The Other Pill: Expanding Access to Pre-Exposure Prophylaxis to Prevent HIV Transmission Among Minors in New York by Neishlos, Aaron & D’Ambrosio, Michael
Fordham Urban Law Journal
Volume 44
Number 3 Drone City Article 5
2017
The Other Pill: Expanding Access to Pre-Exposure
Prophylaxis to Prevent HIV Transmission Among
Minors in New York
Aaron Neishlos
Michael D’Ambrosio
Follow this and additional works at: https://ir.lawnet.fordham.edu/ulj
This Article is brought to you for free and open access by FLASH: The Fordham Law Archive of Scholarship and History. It has been accepted for
inclusion in Fordham Urban Law Journal by an authorized editor of FLASH: The Fordham Law Archive of Scholarship and History. For more
information, please contact tmelnick@law.fordham.edu.
Recommended Citation
Aaron Neishlos and Michael D’Ambrosio, The Other Pill: Expanding Access to Pre-Exposure Prophylaxis to Prevent HIV Transmission
Among Minors in New York, 44 Fordham Urb. L.J. 725 (2017).
Available at: https://ir.lawnet.fordham.edu/ulj/vol44/iss3/5
  725 
THE OTHER PILL:  EXPANDING ACCESS TO 
PRE-EXPOSURE PROPHYLAXIS TO PREVENT 
HIV TRANSMISSION AMONG MINORS IN NEW 
YORK 
Aaron Neishlos & Michael D’Ambrosio* 
Introduction ............................................................................................. 726 
I.  Background:  HIV/AIDS, Treatment, and Prevention .................. 728 
A. What Is HIV? ........................................................................ 728 
B. The Demographics of HIV .................................................. 730 
C. HIV Treatment ...................................................................... 731 
D. PrEP ........................................................................................ 734 
II.  Assessing the Current Legal Landscape ......................................... 740 
A. Informed Consent ................................................................. 740 
B. Minors’ Rights to Consent and the Confidentiality of 
Medical Treatment in New York ........................................ 742 
1. Minors’ Capacity to Consent to Medical Treatment ... 742 
2. Confidentiality of HIV Testing and Treatment ........... 746 
a. Testing and Confidentiality:  Article 27-f .............. 747 
b. Treating HIV As an STI So Minors May 
Consent Without Parental Involvement ................ 750 
c. Governor Andrew Cuomo’s 2016 Proposal ........... 751 
III.  Birth Control .................................................................................... 752 
A. Background:  Minors’ Reproductive Rights ...................... 754 
B. Outcomes of Permitting Teen Access to Birth Control ... 757 
IV.  Creating a PrEP Exception in New York State Law ................... 759 
A. PrEP Functionally Resemble Birth Control ...................... 760 
B. Minors Have a Right to Privacy That Covers Access to 
PrEP ........................................................................................ 761 
                                                                                                                                
* The authors would like to thank Professor Elizabeth Cooper for her unwavering 
enthusiasm for this project, support as a mentor, and for her friendship. The authors would 
also like to thank Julianne Lee (Fordham University School of Law, J.D., 2016) for 
proposing the idea that inspired this Article in February 2015 as well as VOCAL-NY 
(Voices of Community Activists & Leaders, www.vocal-ny.org) who are actively promoting 
public health and just communities every day. 
726 FORDHAM URB. L.J. [Vol. XLIV 
C. Why the Arguments Against Expanding Access to 
PrEP Are Wrong ................................................................... 763 
Conclusion ................................................................................................ 766 
INTRODUCTION 
Reproductive rights should inform the next phase in HIV 
prevention.  Since the 1980s, medicine has made enormous strides in 
preventing and treating HIV infections.  Today, the Food and Drug 
Administration (“FDA”) has approved forty different drugs to treat 
HIV.1  In the last decade, AIDS-related deaths have fallen by more 
than thirty percent.2  Still, new HIV infections predominately impact 
young people.3  In particular, thirteen to twenty-four year olds 
accounted for twenty-two percent of all new HIV-infections in 2014—
a number that has not significantly declined in the last decade.4  To 
address these disparities among young people, the law should afford 
minors the right to access HIV-prophylactic medication. 
In 2012, the FDA approved Truvada—otherwise known as Pre-
Exposure Prophylaxis (“PrEP”)—to prevent HIV infections.5  PrEP 
is a once daily pill composed of two antiretroviral drugs that reduce 
one’s risk of HIV infection by ninety-two to ninety-nine percent.6  
The World Health Organization (“WHO”), Centers for Disease 
Control and Prevention (“CDC”), and United States Public Health 
Service have all endorsed PrEP as an effective means to reduce the 
risk of HIV infection.7  Expanding access to PrEP among thirteen to 
twenty-four year olds could significantly reduce the persistent 
                                                                                                                                
 1. See generally Antiretroviral Drugs Used in the Treatment of HIV Infection, 
U.S. FOOD & DRUG ADMIN. (Oct. 8, 2015), http://www.fda.gov/ForPatients/
Illness/HIVAIDS/Treatment/ucm118915.htm [https://perma.cc/VE24-LKNW]. 
 2. See UNAIDS Reports a 52% Reduction in New HIV Infections Among 
Children and a Combined 33% Reduction Among Adults and Children Since 2001, 
UNAIDS (Sept. 23, 2013), http://www.unaids.org/en/resources/presscentre/
pressreleaseandstatementarchive/2013/september/20130923prunga 
[https://perma.cc/B89N-3PXG]. 
 3. See HIV Among Youth, CTRS. FOR DISEASE CONTROL & PREVENTION, 
http://www.cdc.gov/hiv/group/age/youth/ [https://perma.cc/8U5K-CPEE]. 
 4. See id. 
 5. See Treatment to Prevent HIV Infection (PrEP), AIDS INFONET (Oct. 22, 
2016), http://aidsinfonet.org/fact_sheets/view/160 [https://perma.cc/Y8LH-DLAZ]; 
see also U.S. FOOD & DRUG ADMIN., supra note 1. 
 6. See Robert M. Grant et al., Preexposure Chemoprophylaxis for HIV 
Prevention in Men Who Have Sex with Men, 363 NEW ENG. J. MED. 2587, 2597 
(2010). 
 7. See discussion infra Section I.C. 
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infection rate in this demographic—the demographic most at risk of 
HIV infection.8 
In New York State, however, a minor (a person under eighteen 
years old) may consent to medical treatment only in unique 
circumstances or for specified conditions, such as mental healthcare, 
substance abuse treatment, or reproductive healthcare.9  Minors 
generally do not have the capacity to consent to HIV treatment.10  
PrEP, however, is a prophylactic medication.  It functionally 
resembles birth control in its daily regimen and ability to prevent the 
long-term health effects of sexual activity:  pregnancy for birth control 
and HIV for PrEP.11 
Under New York law, a minor may pursue reproductive healthcare 
without parental consent.12  Reproductive healthcare includes 
accessing prophylactic medication, such as the birth control pill.13  
New York should treat PrEP as another prophylactic medication vital 
to reproductive health.  As such, New York should recognize that, 
under the U.S. Constitution and New York’s Public Health Law, 
minors have a right to privacy that covers their right to access PrEP 
without parental consent.  New York can imbed PrEP within the 
scope of reproductive healthcare through an Executive Order or 
Department of Health (“DOH”) regulation.  If the Executive Branch 
refuses to act, this policy change should be pursued through litigation.  
Through a reproductive rights analysis to a minor’s right to access 
PrEP, New York can take important steps toward reducing the threat 
of HIV infections, ending the AIDS epidemic,14 and preserving 
individual autonomy in medical care. 
This Article analyzes a minor’s capacity to consent to an HIV 
prophylactic medication, PrEP, through a reproductive rights 
                                                                                                                                
 8. See HIV Among Youth, supra note 3. 
 9. See discussion infra Section II.B. 
 10. See discussion infra Section II.A. 
 11. See Grant, supra note 6. 
 12. See discussion infra Section III.A. 
 13. See discussion infra Section III.A.  The Guttmacher Institute has identified 
the following as “contraceptive methods:”  oral contraceptives (birth control or 
morning after pill), injectable, male condom, natural family planning, vaginal ring, 
patch, spermicide, IUD, copper IUD, hormonal IUD, diaphragm or cervical cap, and 
sponge. See Jennifer J. Frost et al., Variation in Service Delivery Practices Among 
Clinics Providing Publicly Funded Family Planning Services in 2010, GUTTMACHER 
INST. 31 (2012), https://www.guttmacher.org/sites/default/files/report_pdf/clinic-
survey-2010.pdf [https://perma.cc/8BVH-Q29G]. 
 14. See generally Ending the AIDS Epidemic in New York State, N.Y. ST. DEP’T 
OF HEALTH (Feb. 2016), https://www.health.ny.gov/diseases/aids/ending_the_
epidemic/ [https://perma.cc/VGE8-Q77N]. 
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framework.  Part I discusses the history of HIV/AIDS as well as the 
medical interventions available to treat the infection.  It also describes 
the emergence of prophylactic medication as the next stage in curbing 
and, potentially, ending the HIV/AIDS epidemic.  Part II outlines the 
law governing a minor’s capacity to consent to medical treatment, 
with a focus on HIV testing and treatment in New York State.  Part 
III discusses the reproductive rights of minors.  In particular, Part III 
recognizes that minors in New York have a right to access 
contraceptive services without parental consent.  Finally, Part IV 
concludes that a minor’s capacity to consent to contraceptive services 
is similar to the capacity to consent to HIV prophylactic medication.  
Minors, therefore, should have a reproductive right to consent to 
PrEP—an HIV prophylactic medication. 
I.  BACKGROUND:  HIV/AIDS, TREATMENT, AND PREVENTION 
While PrEP is a relatively new medical intervention, treatment and 
prevention for HIV/AIDS has been available for several decades.15  
This Section examines what HIV is, who it affects, and what 
prevention and treatment options exist, as well as important and 
necessary conditions to assess how PrEP can intervene in meaningful 
and proactive ways. 
A. What Is HIV? 
HIV is the human immunodeficiency virus; infection with HIV 
leads to a breakdown of the immune system, making the infected 
person vulnerable to opportunistic infections, often resulting in 
acquired immune deficiency syndrome (“AIDS”).16  HIV is 
transmitted from an infected person to an uninfected person by 
exposure to blood, semen, vaginal secretions, or breast milk.17  For 
transmission to occur, fluid must come in contact with a mucous 
membrane or damaged tissue or be directly injected into the 
bloodstream.18  In the United States, HIV is most commonly 
transmitted by anal or vaginal sex or by sharing needles with an 
                                                                                                                                
 15. See generally History of HIV/AIDS Overview, AVERT, http://www.avert.org
/professionals/history-hiv-aids/overview [https://perma.cc/MDN2-H5R8]. 
 16. See HIV Basics, CTRS. FOR DISEASE CONTROL & PREVENTION (Nov. 6, 2015), 
http://www.cdc.gov/hiv/basics/ [https://perma.cc/QQ4L-MUWB]. See also infra notes 
20-21. 
 17. See HIV Transmission, CTRS. FOR DISEASE CONTROL & PREVENTION (Dec. 
14, 2015), http://www.cdc.gov/hiv/basics/transmission.html [https://perma.cc/S7PZ-
BD8X]. 
 18. See id. 
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infected person.19  The risk of transmission varies, depending on the 
type of exposure; however, adherence to post-infection medication 
and treatment can reduce the risk of further transmission by as much 
as ninety-six percent.20 
HIV causes damage by destroying blood cells that help the body 
fight diseases, known as CD4+ or T cells.21  Some people develop 
short-term symptoms within weeks of being infected with HIV, but 
more often people do not experience significant symptoms for several 
years.22  As the HIV virus spreads throughout the body, it destroys 
CD4+ cells, which weakens the body’s immune system.23  Failure to 
obtain early treatment for HIV may exacerbate underlying health 
conditions, such as cardiovascular disease, kidney disease, liver 
disease, and cancer.24  AIDS typically occurs in the late-stage of an 
HIV infection25 when an infected individual’s immune system is 
severely damaged and unable to fight certain diseases and cancers.26  
Individuals with HIV/AIDS also face increased vulnerability to 
certain categories of illnesses that attack weakened immune 
systems.27  These illnesses, together known as “opportunistic 
infections,” include tuberculosis, bacterial pneumonia, septicemia, 
and lymphoma among others.28 
                                                                                                                                
 19. See id. 
 20. See HIV Risk Behaviors, CTRS. FOR DISEASE CONTROL & PREVENTION (Nov. 
16, 2015), http://www.cdc.gov/hiv/risk/estimates/riskbehaviors.html [https://perma.cc/
A44V-83VE].  For example, exposure to HIV during a blood transfusion carries a 
much higher risk of transmission than other exposures, such as oral sex. 
 21. See About HIV/AIDS, CTRS. FOR DISEASE CONTROL & PREVENTION (Dec. 6, 
2015), http://www.cdc.gov/hiv/basics/whatishiv.html [https://perma.cc/E3R7-97EY]. 
 22. See id. 
 23. See id.; HIV Basics, supra note 16. 
 24. See About HIV/AIDS, supra note 21. 
 25. See id. 
 26. See id. 
 27. See HIV Related Opportunistic Infection:  Prevention and Treatment, 
AVERT (May 1, 2015), http://www.avert.org/hiv-opportunistic-infections.htm 
[https://perma.cc/SCX9-M2EW]. 
 28. See id.  The stage to which the disease has progressed often dictates which of 
these infections presents in an individual. For instance, individuals with HIV 
experience higher rates of tuberculosis, malaria, bacterial pneumonia, herpes zoster, 
staphylococcal skin infections and septicemia, while individuals with advanced HIV 
or AIDS are more vulnerable to infections such as pneumocystus pneumonia, 
toxoplasmosis and cryptococcosis. See id. 
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B. The Demographics of HIV 
There are more than 1.2 million people in the United States living 
with HIV.29  As of 2013, approximately 129,000 people in New York 
State were living with HIV or AIDS,30 nearly eighty percent of whom 
live in New York City.31  In 2013, 3800 new individuals were 
diagnosed with HIV in New York State,32 2832 of whom lived in New 
York City.33  In 2014, the number of newly diagnosed individuals in 
New York City dropped slightly to 2718.34  The New York City 
Department of Health and Mental Hygiene (“DOHMH”) estimates 
that one in five HIV-positive people do not know their status.35 
Historically, gay, bisexual, and other men who have sex with men 
(“MSM”) have been the individuals predominantly affected by 
HIV/AIDS.36  This trend continues in New York State, with MSM 
comprising approximately seventy-one percent of new HIV infections 
in 2013.37  The plurality of these new MSM infections occurred in 
people aged twenty-five to thirty-four (thirty-three percent or an 
estimated 966 infections), while thirteen to twenty-four year olds 
accounted for twenty-three percent of new infections.38  Thus, fifty-six 
percent of new infections occur in those thirteen to thirty-four years 
old.  Although most age groups have seen a decline in new HIV 
infections since 2006, the infection rate for thirteen to twenty-four 
year olds has persisted, with the number of new infections in 2013 
only slightly less than in 2006.39 
                                                                                                                                
 29. See HIV in the United States:  At a Glance, CTRS. FOR DISEASE CONTROL & 
PREVENTION (Sept. 29, 2015), http://www.cdc.gov/hiv/statistics/overview/ata
glance.html [https://perma.cc/W3E9-4AEJ]. 
 30. See HIV/AIDS:  An Evolving Epidemic, N.Y.C. AIDS MEM’L (Jan. 2013), 
http://nycaidsmemorial.org/resources/ [https://perma.cc/W2UE-SUV9]. 
 31. See id. 
 32. See New York–2015 State Health Profile, CTRS. FOR DISEASE CONTROL & 
PREVENTION (Dec. 2015), http://www.cdc.gov/nchhstp/stateprofiles/pdf/new_york_
profile.pdf [https://perma.cc/8P9T-398L]. 
 33. See HIV Surveillance Annual Report, 2014, N.Y.C. DEP’T OF HEALTH & 
MENTAL HYGIENE (Dec. 2015), https://www1.nyc.gov/assets/doh/downloads/pdf/
dires/2014-hiv-surveillance-annual-report.pdf [https://perma.cc/Z46H-5YXX]. 
 34. See id. 
 35. See N.Y.C. AIDS MEM’L, supra note 30. 
 36. See HIV in the United States:  At a Glance, supra note 29. 
 37. See HIV Incidence Estimates for New York State 2013, N.Y. ST. DEP’T OF 
HEALTH (Dec. 2015), http://www.health.ny.gov/diseases/aids/general/statistics/docs/
hiv_incidence_2013.pdf [https://perma.cc/5NA2-TVFY]. 
 38. See id. 
 39. See id. 
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It should be noted that HIV infection disproportionately affects 
racial minorities.40  In 2013, African Americans and Latinos made up 
only thirty-two percent of New York State’s population, but almost 
seventy percent of estimated new HIV infections.41  At the end of 
2012, there were approximately 496,500 African Americans living 
with HIV in the U.S., forty-one percent of all Americans living with 
the virus.42  In 2013, African Americans constituted fifty-four percent 
of total deaths attributed to HIV/AIDS.43  The estimated HIV 
infection rate for African Americans was six times higher than that of 
whites, and the rate for Latinos was five times higher.44  Nationally, 
the racial infection rate disparity is even greater.  African American 
and Latino MSM account for eighty percent of new infections of 
MSM under the age of twenty-five, even though they typically engage 
in less risky behavior than white MSM.45 
C. HIV Treatment 
In contrast to the first fifteen years of the HIV/AIDS epidemic, 
there are now numerous treatment options available that suppress the 
virus, allowing individuals to live symptom-free for longer periods.46  
Combining these medications, referred to as HAART (Highly Active 
Antiretroviral Therapy),47 limits or slows down the destruction of the 
immune system and the development of AIDS, improves health, and 
                                                                                                                                
 40. See id. 
 41. See id. 
 42. See HIV Among African Americans, CTRS. FOR DISEASE CONTROL & 
PREVENTION (Feb. 4, 2016), http://www.cdc.gov/hiv/group/racialethnic/african
americans/ [https://perma.cc/L6FV-4F7T].  African Americans, however, only 
comprise twelve percent of the U.S. population. 
 43. See id. 
 44. See N.Y. ST. DEP’T OF HEALTH, supra note 37. 
 45. Donald G. McNeil Jr., Poor Black and Hispanic Men Are the Face of H.I.V., 
N.Y. TIMES (Dec. 4, 2013), http://www.nytimes.com/2013/12/05/us/poor-black-and-
hispanic-men-are-face-of-hiv.html [https://perma.cc/JS5R-776K].  While young Black 
MSM have been shown to take fewer risks than their white peers (i.e., they had fewer 
partners, engaged in fewer acts of sex while under the influence, and used condoms 
more often), other risk factors, such as a lack of health insurance and the fact that 
more of their partners were older black men (who are more likely to have untreated 
HIV than older white men), may contribute to an explanation for this monumental 
spike. 
 46. HIV/AIDS, NAT’L INST. OF ALLERGY & INFECTIOUS DISEASES, 
http://www.niaid.nih.gov/topics/hivaids/understanding/treatment/pages/default.aspx 
[https://perma.cc/UF7X-KW8F]. 
 47. Marcie F. Rubin et al., Examination of Inequalities in HIV/AIDS Mortality in 
the United States from a Fundamental Cause Perspective, 100 AM. J. PUB. HEALTH 
1053 (2009) (defining HAART and explaining its effects on mortality). 
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reduces the potential for transmitting the virus to others.48  Although 
these treatments have transformed HIV/AIDS into more of a chronic 
condition than the death sentence it once was, there remains no cure 
for HIV or AIDS.  In 2013 an estimated 12,963 people died from HIV 
in the United States.49 
The FDA has approved forty antiretroviral drugs (“ARVs”) for 
HIV treatment.50  ARVs are organized into six major drug classes and 
each group attacks HIV in a different manner.51  Medical 
practitioners generally recommend that HIV-positive persons take 
two or more ARVs from different groups at a time.52  Combining 
ARVs significantly reduces the rate at which HIV becomes resistant 
to the drugs, improving their efficacy.53 
Although the “cocktail” of available treatments is a vast 
improvement over previous medications, modern medications still 
present difficulties, including potential side effects and unknown 
harms that arise from long-term use.54  In light of the relative 
uncertainty regarding the possible harms of long-term treatment, 
medical experts only recently concluded that the benefits of starting 
                                                                                                                                
 48. See About HIV/AIDS, supra note 21. 
 49. See HIV in the United States:  At a Glance, supra note 29. 
 50. See U.S. FOOD & DRUG ADMIN., supra note 1. 
 51. Types of HIV/AIDS Antiretroviral Drugs, NAT’L INST. OF ALLERGY & 
INFECTIOUS DISEASES, https://www.niaid.nih.gov/diseases-conditions/types-hivaids-
antiretroviral-drugs [https://perma.cc/B7Q5-3QZF] (last updated Sept. 23, 2013) 
(explaining that the classes are entry inhibitors, fusion inhibitors, reverse 
transcriptase inhibitors, integrase inhibitors, protease inhibitors, and multi-class 
combination products; each class of drug attempts to interfere or interrupt the virus 
cells from replicating or entering a patient’s own cells at a specific point during the 
virus’ reproduction cycle). 
 52. Id.  This approach is called “HAART.” See Rubin, supra note 47, at 1053. 
 53. Drug Resistance, AIDS.GOV, https://www.aids.gov/hiv-aids-basics/just-diagno
sed-with-hiv-aids/treatment-options/drug-resistance/ [https://perma.cc/X2V9-JQGN] 
(last updated Apr. 20, 2016). 
 54. Long-Term Side Effects, AIDS.GOV, https://www.aids.gov/hiv-aids-basics/just-
diagnosed-with-hiv-aids/treatment-options/side-effects/ [https://perma.cc/94PJ-
RDT4] (last updated Aug. 7, 2009) (listing “Anemia (abnormality in red blood cells), 
Diarrhea, Dizziness, Fatigue, Headaches, Nausea and vomiting, Pain and nerve 
problems, Rash” as some of the short-term side effects of ARV treatments; also 
listing lipodystrophy (a problem in the way the body uses and stores fat), insulin 
resistance, lipid abnormalities, decrease in bone density, and lactic acidosis (a buildup 
of cellular waste in the body)); see also David France, Another Kind of AIDS Crisis, 
N.Y. MAG. (Nov. 1, 2009), http://nymag.com/health/features/61740/ [https://perma.cc/
7UJE-VQ9Y] (stating that “A striking number of HIV patients are living longer but 
getting older faster—showing early signs of dementia and bone weakness usually 
seen in the elderly.”). 
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treatment early outweigh the risks.55  However, long-term health 
concerns still exist.56  Beyond health concerns, there are also practical 
and theoretical matters to consider.  HIV treatment is complicated, 
intensive, and costly.57  Though treatment has become less 
burdensome and more effective over time, treatment regimens still 
generally require taking various types of medication concurrently.58  
Medications often have specific timing and dietary restrictions, with 
which adherence is paramount.59  The strictures of treatment may be 
especially daunting for an adolescent patient who must manage 
medical appointments and treatment administration along with other 
life demands.  If an adolescent patient forgoes or avoids certain 
components of treatment, the overall benefit of treatment may prove 
ineffective. 
Although there is potential for harm and the treatment regimens 
are complex, treatment offers clear benefits, significantly reducing 
morbidity and mortality regardless of age, race, sex, or method of 
transmission.60  Moreover, treatment can reduce the risk of viral 
transmission through sexual activity by up to ninety-six percent, a 
significant public health consideration in the initiation of ARV 
treatment.61  This discovery of reduced transmission rates has the 
                                                                                                                                
 55. See Maggie Fox, Early Treatment Best for HIV, NBC NEWS (May 27, 2015), 
http://www.nbcnews.com/health/health-news/early-treatment-best-hiv-study-confirms
-n365461 [https://perma.cc/TBN2-XRN5]. 
 56. See Sean Cahill & Robert Valadéz, Growing Older with HIV/AIDS, 103 AM. 
J. PUB. HEALTH e7 (2013) (“More research is needed to sort out the causality of 
HIV/AIDS and HIV treatments in comorbidities, and the interactions of 
antiretrovirals and other medications.”). 
 57. HIV Cost-Effectiveness, CTRS. FOR DISEASE CONTROL & PREVENTION, 
http://www.cdc.gov/hiv/prevention/ongoing/costeffectiveness/ [https://perma.cc/9SCH
-RVM6] (last updated Sept. 23, 2013) (estimating the lifetime treatment cost of an 
HIV infection at $379,668 in 2010 dollars).  By contrast, HIV testing is noninvasive 
and occurs quickly. See HIV Counseling & Testing Resource Directory, N.Y. ST. 
DEP’T OF HEALTH, http://www.health.ny.gov/diseases/aids/providers/testing/docs/
testing_toolkit.pdf [https://perma.cc/B58T-3U23] (last updated June 2015). 
 58. HIV and Its Treatment, AIDS INFO, https://aidsinfo.nih.gov/education-
materials/fact-sheets/21/51/hiv-treatment—the-basics# [https://perma.cc/FCF7-
NHB4] (last updated Sept. 13 2016).  However, more than one drug can be combined 
into the same pill. 
 59. See generally Your Diet and Anti-HIV Drugs, AIDSMAP (Aug. 2016), 
http://www.aidsmap.com/Your-diet-and-anti-HIV-drugs/page/2029328/ 
[https://perma.cc/K4SN-HJL2]. 
 60. Palella, F. et. al., Declining Morbidity and Mortality Among Patients with 
Advanced Human Immunodeficiency Virus Infection, 338 NEW ENG. J. MED. 853 
(Mar. 26, 1998), http://www.nejm.org/doi/full/10.1056/NEJM199803263381301 
[https://perma.cc/PU3M-MCQS]. 
 61. Myron S. Cohen et al., Prevention of HIV-1 Infection With Early 
Antiretroviral Therapy, 365 NEW ENG. J. MED. 493, 503 (2011). 
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potential to significantly change the focus of HIV treatment and 
prevention. 
The use of ARV treatment for children and adolescents presents 
some unique concerns.  The market for pediatric ARV drugs is small 
and there are few children to participate in clinical trials;62 as such, 
most adult-approved drugs lack an FDA pediatric label indication.63  
Thus, physicians often prescribe ARV treatment to minors without 
always knowing the effective dosing.64  The federal Department of 
Health and Human Services (“HHS”) cautions physicians to consult 
with pediatric HIV specialists to identify patient and drug-specific 
concerns and to investigate the availability of any clinical data on 
each drug’s use in minors.65 
D. PrEP 
In 2014, the CDC issued guidelines endorsing a new mode of HIV 
prevention.66  PrEP is a daily drug regimen, utilized as a prevention 
strategy by individuals who do not have HIV, but who engage in 
behavior that puts them at a higher risk of contracting it.67  PrEP 
currently consists of one tablet of Truvada, a combination of two HIV 
medications:  tenofivir and emtricitabine.68  No health organization 
                                                                                                                                
 62. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection, 
AIDSINFO, DEP’T OF HEALTH & HUM. SERVS., https://aidsinfo.nih.gov/guidelines/
html/2/pediatric-arv-guidelines/107/the-use-of-antiretroviral-agents-not-approved-
for-use-in-children [https://perma.cc/8H74-HZHC] (last updated Nov. 1, 2012).  
Importantly, however, the use of ARV treatment by pregnant women living with 
HIV can reduce the risk of HIV transmission to the child to below five percent 
(whereas without treatment, the risk of transmission is between fifteen and forty-five 
percent). See Prevention of Mother-to-Child Transmission (PMTCT) of HIV, 
AVERT, http://www.avert.org/professionals/hiv-programming/prevention/prevention-
mother-child [https://perma.cc/QBS8-N29Y] (last updated Oct. 5, 2016). 
 63. See AIDSINFO, supra note 62. 
 64. See id. 
 65. See id. 
 66. See generally Preexposure Prophylaxis for the Prevention of HIV Infection in 
the U.S., CTRS. FOR DISEASE CONTROL & PREVENTION (2014), http://www.cdc.gov/
hiv/pdf/prepguidelines2014.pdf [https://perma.cc/XC8U-9USC]. 
 67. Pre-Exposure Prophylaxis (PrEP), AIDS.GOV, https://www.aids.gov/hiv-aids-
basics/prevention/reduce-your-risk/pre-exposure-prophylaxis/ 
[https://perma.cc/6QUH-VHYA] (last updated Jan. 29, 2016). 
 68. Id.; see also Guidelines for the Use of Antiretroviral Agents in HIV-1-
Infected Adults and Adolescents, DEP’T OF HEALTH & HUM. SERVS., https://aidsinfo.
nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf [https://perma.cc/24AR-
PKAL] (last updated July 14, 2016). 
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recommends any other drug for the purposes of PrEP.69  The FDA 
approved Truvada as PrEP for public consumption on July 16, 2012.70 
Clinical studies have demonstrated that PrEP is highly effective at 
reducing the risk of HIV transmission.  A 2010 study (“the iPrEx 
study”) compared Truvada with a placebo pill in nearly 2500 subjects, 
consisting of MSM and transwomen in six countries.71  The study 
demonstrated that for individuals with detectable levels of the drugs 
in their blood (i.e., indicating that the medication was being taken 
regularly), HIV transmission rates dropped by ninety-two percent.72  
Further analyses indicated that daily adherence to PrEP may reduce 
an individual’s likelihood of contracting HIV by ninety-nine 
percent.73  In a study consisting of men and women in serodiscordant 
couples, couples in which one partner had HIV but the other did 
not,74 PrEP reduced the risk of HIV transmission by up to ninety 
                                                                                                                                
 69. PrEP 101, BIRMINGHAM AIDS OUTREACH, http://www.birminghamaids
outreach.org/#!prep/c241g [https://perma.cc/N3CU-ZUFM] (“Although other HIV 
drugs are currently being studied, no other pill besides Truvada . . . has been shown 
to prevent HIV infection.  Therefore, you should not use any other HIV pill in place 
of Truvada.”). 
 70. FDA approves first drug for reducing the risk of sexually acquired HIV 
infection, U.S. FOOD & DRUG ADMIN. (July 16, 2012), http://www.fda.gov/News
Events/Newsroom/PressAnnouncements/ucm312210.htm [https://perma.cc/PQG5-
S2CA]. 
 71. See Grant, supra note 6, at 2587-99 (studying Peru, Ecuador, South Africa, 
Brazil, Thailand, and the United States). 
 72. See id.; see also AIDS INFONET, supra note 5 (noting that research showed 
over ninety percent reduction in HIV infections when PrEP was taken four times a 
week). 
 73. See AIDS INFONET, supra note 5.  In a recent study, 100% of the participants 
remained HIV-free during the 2.5 years of observation.  The study was the first to 
show results from a “demonstration project,” which examines medication use outside 
the rigid confines of a placebo-controlled randomized controlled trial.  This makes its 
findings a somewhat better prediction of PrEP’s effects in a real-world setting. See 
Jonathan E. Volk et al., No New HIV Infections with Increasing Use of HIV 
Preexposure Prophylaxis in a Clinic Practice Setting, CLINICAL INFECTIOUS DISEASES 
61, 1601-03 (2015); see also Benjamin Ryan, 100% Efficacy for Gays Who Adhered in 
PrEP Study; Most Didn’t, POZ (July 22, 2014), https://www.poz.com/article/iPrEx-
OLE-results-25922-2484 [https://perma.cc/2PHG-47VT]. However, in early 2016, one 
patient, who used PrEP as directed, became infected with HIV, showing that while 
Truvada may be especially effective, it does not eliminate the risk of contracting 
HIV. See Trenton Straube, Meet the Man Who Got HIV While on Daily PrEP, POZ 
(Mar. 3, 2016), https://www.poz.com/article/meet-man-got-hiv-daily-prep 
[https://perma.cc/9QQ3-UC2C]. 
 74. A “serodiscordant” relationship is one in which one partner is HIV-positive 
and the other is HIV-negative. See Raymond A. Smith, “Couples,” BODY (1998), 
http://www.thebody.com/content/art14009.html [https://perma.cc/U35Z-F8YJ]. 
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percent.75  Among injection drug users, a daily tablet containing only 
tenofivir reduced the risk of contracting HIV by nearly forty-nine 
percent; for study participants who had detectable tenofivir in their 
blood (i.e., regular use of the medication), it reduced the risk of 
infection by seventy-four percent.76  Despite its efficacy, PrEP is 
intended for use with condoms and clean needles, so that each 
method can compensate for the deficits of the other.77  PrEP has no 
reported major side effects, and minor side effects, such as nausea, 
subside over time.78 
Although Truvada was approved by the FDA for prevention 
purposes in 2012, the CDC only amended its guidelines in May 
2014.79  The guidelines recommend that individuals who are at “high 
risk” for contracting HIV from sex or injection drug use consider 
using PrEP to mitigate the risk of contracting the virus.80  Those at 
“high risk” include any HIV-negative individual in an ongoing sexual 
relationship with an HIV-positive partner; any HIV-negative gay or 
bisexual man not in a mutually monogamous relationship who has 
                                                                                                                                
 75. Jared M. Baeten et al., Antiretroviral Prophylaxis for HIV-1 Prevention 
Among Heterosexual Men and Women, 367 NEW ENG. J. MED. 399, 405 (2012), 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770474/ [https://perma.cc/TP8M-
SE3F]. 
 76. Kachit Choopanya, Antiretroviral Prophylaxis for HIV Infection in Injecting 
Drug Users in Bangkok, Thailand, 381 LANCET 2083, 2088 (2013). 
 77. See HIV/AIDS:  Pre-Exposure Prophylaxis (PrEP), CTRS. FOR DISEASE 
CONTROL & PREVENTION, http://www.cdc.gov/hiv/risk/prep/index.html [https://perma
.cc/B8N7-MUZC] (last updated Sept. 19, 2016); see also Truvada:  Important Safety 
Information, GILEAD (2016), https://start.truvada.com/hcp/important-safety-infor
mation# [https://perma.cc/JG6E-Q89L].  A 2015 study demonstrated that MSM who 
always use condoms and who adhere to the daily regimen of Truvada at a rate of at 
least ninety percent have an estimated ninety-two percent lower HIV risk than those 
who never use condoms or PrEP.  In contrast, MSMs who only use condoms have a 
seventy percent lower risk of an HIV infection. See Benjamin Ryan, How Well Do 
Condoms and PrEP Prevent HIV Among Gay and Bi Men?, POZ (Feb. 4, 2015), 
https://www.poz.com/article/condom-PrEP-efficacy-26766-8889 
[https://perma.cc/9PBN-BTLY]. 
 78. HIV/AIDS:  PrEP, CTRS. FOR DISEASE CONTROL & PREVENTION (Dec. 14, 
2015), http://www.cdc.gov/hiv/basics/prep.html [https://perma.cc/J3Q4-F3JY]; see also 
Mark Joseph Stern, There Is a Daily Pill That Prevents HIV. Gay Men Should Take 
It, SLATE (Jan. 6, 2014), http://www.slate.com/blogs/outward/2014/01/06/truvada_
prep_hiv_gay_men_should_take_pre_exposure_prophylaxis.html 
[https://perma.cc/2DT9-23KX] (stating that “Truvada has virtually no side effects”); 
but see France, supra note 54 (outlining possible harms with long-term treatment). 
 79. See Preexposure Prophylaxis for the Prevention of HIV Infection in the U.S., 
supra note 66.  As discussed, Truvada was an existing ARV drug, suitable for use as 
treatment after infection, before being approved for PrEP. See DEP’T OF HEALTH & 
HUM. SERVS., supra note 68. 
 80. See generally Preexposure Prophylaxis for the Prevention of HIV Infection in 
the U.S., supra note 66, at 12. 
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had anal sex without using a condom or has been diagnosed with a 
sexually transmitted disease in the six months preceding PrEP 
treatment; or any HIV-negative heterosexual man or woman who 
does not regularly use condoms during sex with partners of unknown 
HIV status.81  The CDC also recommends PrEP for HIV-negative 
individuals who have injected drugs in the six months preceding PrEP 
treatment and who have shared needles or been in drug treatment 
during those same six months.82 
A federal interagency working group led by the CDC developed 
the 2014 Clinical Practice Guidelines; they reflect input from 
stakeholders across the care spectrum, including providers, people 
living with HIV, partners, and other affected communities.83  The 
guidelines discuss whether PrEP is safe and effective for adolescents, 
but conclude that current data is insufficient.84  The guidelines 
recommend that states consider the benefits and risks of adolescent 
use of PrEP in the context of local laws about autonomy in health 
care decision-making by minors.85  However, while noting that past 
HIV prevention methods have not been adequately successful, the 
guidelines suggest that additional HIV prevention tools are necessary 
to reduce the rate of new infections, “especially (but not exclusively) 
among young adult and adolescent MSM of all races and 
Hispanic/Latino ethnicity and for African American 
heterosexuals . . . .”86  Importantly, the guidelines note that while 
parental or guardian involvement often may be desirable when 
considering an adolescent minor’s use of PrEP, it may sometimes be 
adverse to the safety of the adolescent.87 
Since its introduction, PrEP has gained a lot of focus and attention, 
both supporting and opposing its use.  In July 2014, the WHO issued 
guidelines strongly recommending MSM to consider taking PrEP as a 
                                                                                                                                
 81. See id. 
 82. See id. at 30. 
 83. Guidelines and Recommendations, CTRS. FOR DISEASE CONTROL & 
PREVENTION (Aug. 23, 2016), http://www.cdc.gov/hiv/guidelines/index.html 
[https://perma.cc/5L6T-LE6Z]. 
 84. See Preexposure Prophylaxis for the Prevention of HIV Infection in the U.S., 
supra note 66, at 9, 43. 
 85. See id. at 42-43. 
 86. See id. at 13; see also McNeil, supra note 45 (explaining higher seroprevalence 
and infection rates for young men of color). 
 87. Preexposure Prophylaxis for the Prevention of HIV Infection in the U.S., 
supra note 66, at 42; see also discussion infra Section III.A. 
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method of preventing HIV infection.88  New York Governor Andrew 
Cuomo, as a part of his pledge to ends the HIV/AIDS epidemic in the 
state by 2020, is committed to providing access to PrEP to high-risk 
HIV-negative individuals to keep them from becoming infected with 
HIV.89  Governor Cuomo has launched the PrEP Assistance Plan 
(“PrEP-AP”), which reimburses service providers who treat eligible 
individuals engaging in high-risk activity and seeking primary medical 
care from experts in HIV prevention.90  PrEP-AP further ensures that 
such individuals, if uninsured, receive PrEP through a manufacturer-
patient assistance program.91 
In his endorsement of PrEP, Governor Cuomo stated that 
“expanding PrEP assistance is a critically important step toward 
eradicating the AIDS epidemic in [New York] state.”92  His plan 
recognizes that while New York has made strides in reducing HIV 
infections for some individuals engaging in high-risk behavior, 
including injection drug users, progress in reducing infection among 
MSM, and particularly young MSM, has been slow.93  Medical experts 
and advocates for persons with HIV have also endorsed the use of 
PrEP as a safe and effective HIV prevention tool.94 
PrEP, however, suffers from an image problem.  PrEP’s most 
vehement opponents come from within the HIV/AIDS activist 
community.95  Many are concerned that once on PrEP, gay men will 
                                                                                                                                
 88. Melissa Hellmann, WHO Says All Men Who Have Sex With Men Should 
Take Antiretroviral Drugs, TIME (July 11, 2014), http://time.com/2975573/who-hiv-
aids-gay-men-homosexual-epidemic-rise/ [https://perma.cc/23LW-J2UM]. 
 89. Pre-Exposure Prophylaxis Assistance Program (PrEP-AP), N.Y. ST. DEP’T OF 
HEALTH, https://www.health.ny.gov/diseases/aids/general/resources/adap/prep.htm 
[https://perma.cc/749Z-X7WP]. 
 90. Id. 
 91. Id. 
 92. Governor Cuomo Announces Program to Protect High-Risk Individuals from 
HIV, PRESS OFF. OF GOVERNOR ANDREW CUOMO (May 12, 2015), 
https://www.governor.ny.gov/news/governor-cuomo-announces-program-protect-
high-risk-individuals-hiv [https://perma.cc/WAN4-FP3Z]. 
 93. Daniel Costa-Roberts, 8 Things You Didn’t Know About Truvada, PBS 
NEWSHOUR (Apr. 12, 2015), http://www.pbs.org/newshour/rundown/8-things-didnt-
know-truvadaprep/ [https://perma.cc/W5VL-PDMN]. 
 94. See, e.g., Stern, supra note 78 (“Basically Truvada is a miracle drug.”); see 
also Alice Park, There’s a Drug That Prevents HIV. Let’s Use It, TIME (Nov. 16, 
2015), http://time.com/4114402/aids-hiv-drug-prep/ [https://perma.cc/P7CF-J6LR] 
(“And it’s time for more cities and states to take San Francisco’s lead and figure out 
ways to make PrEP available to those who can benefit most.”). 
 95. Stern, supra note 78; see generally Tom Myers, HIV Prevention Pill Will Do 
More Harm Than Good, U.S. NEWS (Aug. 3, 2012), http://www.usnews.com/
opinion/articles/2012/08/03/hiv-prevention-pill-will-do-more-harm-than-good-hiv-pill-
will-give-a-false-sense-of-security [https://perma.cc/S3RA-6T98] (Myers, the author, 
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stop using other precautions to reduce the transmission of HIV.96  In 
fact, before the FDA approved Truvada, the AIDS Healthcare 
Foundation lobbied the agency to reject the drug for use as PrEP.97  
Regan Hofmann, the former editor-in-chief of Poz magazine has 
derided PrEP as a “profit-driven sex toy for rich Westerners,”98 while 
Dan Savage, a nationally syndicated sex columnist, has described 
PrEP-users as “self-identified idiots who can only be saved by a 
vaccine.”99  Critics have also expressed concern that HIV strains may 
become resistant to PrEP, as well as the physiological harm that may 
result from long-term use of Truvada.100 
Several studies have demonstrated, however, that PrEP use does 
not lead to “sexual risk compensation” (i.e., opting out of other safe 
sex practices).101  Nonetheless, PrEP’s opponents have denigrated 
individuals who have taken advantage of the medication, labeling 
them “Truvada whores”102—individuals who take the drug to excuse 
or justify their unsafe sexual behavior.103  PrEP’s advocates have since 
reappropriated the term and have recast PrEP as “a drug that 
represents the possibility of sexual autonomy and an opportunity to 
push against the normative model” of heterosocialized queer life.104 
                                                                                                                                
is the chief of public affairs and general counsel for the AIDS Healthcare 
Foundation). 
 96. Myers, supra note 95. 
 97. Id.  The AIDS Healthcare Foundation is a Los Angeles-based non-profit 
organization that provides medicine and advocacy to people with HIV/AIDS.  It is 
the largest provider of HIV/AIDS medical care in the United States. See AIDS 
HEALTHCARE FOUND., http://www.aidshealth.org/#/about [https://perma.cc/99EX-
7XRS]. 
 98. See Christopher Glazek, Why Is No One On the First Treatment to Prevent 
H.I.V.?, NEW YORKER (Sept. 30, 2013), http://www.newyorker.com/tech/elements/
why-is-no-one-on-the-first-treatment-to-prevent-h-i-v [https://perma.cc/4WWY-
SC9E]. 
 99. Richard Morgan, Sex and the H.I.V. Morning-After Pill, N.Y. TIMES (June 28, 
2013), http://www.nytimes.com/2013/06/29/opinion/sex-and-the-hiv-morning-after-
pill.html [https://perma.cc/2N7Y-F2BS]. 
 100. See Myers, supra note 95. 
 101. See, e.g., Study Shows PrEP Does Not Lead to Increases in Risky Sex Among 
Gay Men, CTR. FOR HIV IDENTIFICATION PREVENTION & TREATMENT SERVS. (Sept. 
2013), http://chipts.ucla.edu/study-shows-prep-does-not-lead-to-increases-in-risky-sex
-among-gay-men/ [https://perma.cc/756S-PZL5]. 
 102. See Park, supra note 94. 
 103. See Jim Burress, ‘Truvada Whores’ Stigma Endures Among Doctors and 
LGBTS, ADVOCATE (Aug. 11, 2014), http://www.advocate.com/health/2014/08/11/tru
vada-whore-stigma-endures-among-doctors-and-lgbts [https://perma.cc/Z7TN-RN55]. 
 104. See Aaron Braun, ‘Truvada Whores’ and the Class Divide, PACIFIC 
STANDARD (Aug. 17, 2015), http://www.psmag.com/health-and-behavior/truvada-
whores-and-the-aids-class-divide [https://perma.cc/7YED-X7VJ].  Though the author 
does not use that term, by “heterosocialized queer life,” we refer to the experience of 
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The social critics of PrEP raise valid concerns.  Although PrEP 
represents the next stage in the scientific study and medical treatment 
of HIV/AIDS, science and medicine must coincide with social norms 
and legal rules.  The next Part of this Article addresses the legal rules 
governing an individual’s access to PrEP. 
II.  ASSESSING THE CURRENT LEGAL LANDSCAPE 
This Part outlines the laws governing a minor’s capacity to consent 
to medical treatment, focusing on the capacity to consent to HIV 
testing and treatment.  In special circumstances a minor may be able 
to consent to HIV testing and treatment, notwithstanding the typical 
requirement of parental consent. 
A. Informed Consent 
Over a hundred years ago, writing for the New York Court of 
Appeals in Schloendorff v. Society of New York Hospital, then-Judge 
Benjamin Cardozo stated, “[e]very human being of adult years and 
sound mind has a right to determine what shall be done with his 
body . . . .”105  Throughout the past century, U.S. courts have 
uniformly held that self-determination and individual autonomy are 
the principles underlying the legal doctrine of informed consent—that 
is, freedom from non-consensual interference with one’s person.106 
Informed consent imposes two duties on medical providers:  (1) the 
duty to disclose information and (2) the duty to obtain informed 
consent from the patient.107  The provider must disclose alternative 
treatments as well as “reasonably foreseeable risks and benefits 
involved as a reasonable medical, dental or podiatric practitioner 
                                                                                                                                
being a queer or LGBT-identified person in a world where heterosexuality is the 
normal or preferred sexual orientation, and where, at least implicitly, queer or 
LGBT-identified individuals are pressured to assimilate into such a model of 
existence. 
 105. 211 N.Y. 125, 129 (1914) (holding that a surgeon who performs an operation 
without patient consent commits an assault). 
 106. Paula Walter, The Doctrine of Informed Consent:  To Inform or Not to 
Inform?, 71 ST. JOHN’S L. REV. 543, 545-46 (1997) (citing Cruzan v. Mo. Dep’t of 
Health, 497 U.S. 261, 269 (1990) (citing Union Pacific R.R. Co. v. Botsford, 141 U.S. 
250, 251 (1891) (“No right is held more sacred, or is more carefully guarded, by the 
common law, than the right of every individual to possession and control of his own 
person from all restraint or interference of others, unless by clear and unquestionable 
authority of law.”))). 
 107. See N.Y. PUB. HEALTH LAW § 2805-d (McKinney 2016); N.Y. MENTAL HYG. 
LAW § 80.03(c) (McKinney 2011) (“Capacity to consent” requires that a person 
understand his or her condition, the nature and purpose of the proposed and 
alternative treatments, and the predictable risks and benefits of the proposed and 
alternative treatments). 
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under similar circumstances would have disclosed.”108  To grant 
informed consent, the patient must (i) be competent, (ii) have the 
capacity to consent, and (iii) voluntarily give consent, free from 
coercion.109  Without all three elements, a person has not given 
informed consent.  And without informed consent, a medical provider 
may not administer medical treatment absent an emergency.110 
A patient may provide informed consent orally, in writing, or a 
medical provider may infer consent through a patient’s conduct (“e.g., 
holding out an arm for a shot”).111  A medical provider’s failure to 
obtain informed consent before treatment may result in liability for 
medical malpractice.112 
“Competency” is an essential element in the laws governing 
informed consent and patient confidentiality.  Competency 
encompasses the ability of a person to make decisions about her own 
interests.113  If a person is not competent, then her decisions have no 
legal effect.114  Adults are presumed competent unless adjudicated 
“incompetent.”115  When the state determines that a person’s age or 
disability interferes with her ability to make decisions for herself, the 
state may invoke its parens patriae power to appoint a legal 
guardian.116  The state has this power because it has a compelling 
interest in providing care for citizens who are unable to care for 
themselves.117 
Minors are generally considered incompetent.118  Even though New 
York law considers any person under eighteen years old to be a 
minor, the law no longer sets a “blanket” age at which one becomes 
                                                                                                                                
 108. N.Y. PUB. HEALTH LAW § 2805-d(1) (McKinney 2016).  New York State uses 
the “reasonable physician” standard, rather than the “reasonable patient” standard 
that has been adopted by a majority of states. 
 109. See Bruce J. Winick, Competency to Consent to Treatment:  The Distinction 
Between Assent and Objection, 28 HOUS. L. REV. 15 (1991) (citations omitted). 
 110. See N.Y. PUB. HEALTH LAW § 2805-d(4)(c) (McKinney 2016). 
 111. See JESSICA FEIERMAN ET AL., N.Y. CIV. LIBERTIES UNION, TEENAGERS, 
HEALTH CARE & THE LAW:  A GUIDE TO THE LAW ON MINORS’ RIGHTS IN NEW 
YORK STATE 12 (2001). 
 112. Section 2805-d, supra note 107. 
 113. Winick, supra note 109, at 16. 
 114. Id. at 22. 
 115. Id. 
 116. See Mills v. Rogers, 457 U.S. 291, 296 (1982). 
 117. Rivers v. Katz, 495 N.E.2d 337, 343 (1986) (citing Addington v. Texas, 441 
U.S. 418, 426 (1979)). 
 118. See generally FED. R. CIV. P. 17(c)(2). 
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“competent.”119  Courts determine a minor’s “competence” to 
participate in discrete tasks, such as managing property, standing trial, 
or consenting to medical treatment.120  For example, in New York, a 
fourteen year old may be competent to testify as a witness,121 but 
incompetent to consent to medical treatment.122  The next section 
discusses a minor’s capacity to consent to medical treatment in New 
York. 
B. Minors’ Rights to Consent and the Confidentiality of Medical 
Treatment in New York 
New York law allows minors to consent to medical treatment and 
receive confidential treatment from a licensed physician—in special 
circumstances.  Policy considerations, including the prevention and 
treatment of HIV/AIDS, underlie these special circumstances.  This 
section outlines the provisions in New York’s legal code that allow a 
minor to consent to and receive confidential medical treatment. 
1. Minors’ Capacity to Consent to Medical Treatment 
New York law defines any person under eighteen years old as a 
“minor.”123  In general, a minor lacks authority to consent to her own 
medical treatment.124  Instead, medical providers must obtain 
informed consent from an authorized person, such as a biological or 
adoptive parent, legal guardian, or caregiver.125  “Parental consent” 
laws are primarily motivated by the perception that minors are not 
capable of making medical decisions on their own.126  Parents also 
have their own rights, which include the right to custody, care, and 
                                                                                                                                
 119. See N.Y. GEN. OBLIG. LAW § 1-202 (McKinney 2015); N.Y. C.P.L.R. 105(j) 
(McKinney 2015). 
 120. Winick, supra note 109, at 23 (citing Katz, 495 N.E.2d at 341-43). 
 121. See Olshansky v. Prensky, 172 N.Y.S. 856 (N.Y. App. Div. 1918) (citing 
People v. Linzey, 29 N.Y.S. 560 (N.Y. Sup. Ct. 1894)); 8 Carmody-Wait 2d § 56:160-
62. 
 122. N.Y. PUB. HEALTH LAW § 2504(1) (unless the person is the parent of a child 
or has married). 
 123. See N.Y. GEN. OBLIG. LAW § 1-202 (McKinney 2015); N.Y. C.P.L.R. 105(j) 
(McKinney 2015). 
 124. See Jennifer L. Rosato, What Are the Implications of Roper’s Dilemma for 
Adolescent Health Law?, 20 J. OF L. & POL’Y 167, 174 (2011); Jennifer L. Rosato, 
The Ultimate Test of Autonomy:  Should Minors Have a Right to Make Decisions 
Regarding Life-Sustaining Treatment?, 49 RUTGERS L. REV. 1, 18 (1996). 
 125. David M. Vukadinovich, Minors’ Rights to Consent to Treatment:  Navigating 
the Complexity of State Laws, 37 J. HEALTH L. 667, 672 (2004). 
 126. See Rosato, The Ultimate Test of Autonomy, supra note 124, at 18. 
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control of their children.127  This affects the right of a minor to 
consent to medical treatment because it typically falls within a 
parent’s constitutional rights to maintain the health and well-being of 
their child.128 
New York’s Public Health Law, however, builds in two exceptions 
to parental consent requirements.  First, the “status” exception allows 
a person under eighteen years old to consent to medical treatment if 
she is a parent, married, serving in the military, or pregnant.129  
Although pregnant minors may only consent to medical and dental 
treatment related to their own prenatal care,130 upon giving birth, the 
minor may consent to all forms of medical treatment for herself and 
her child.131  In these circumstances, the law presumes that the minor 
has the requisite capacity to consent to her own medical treatment. 
Second, New York law recognizes a “treatment” exception for 
minors who understand—as perceived by the medical provider—the 
risk and benefits of reproductive healthcare,132 mental health 
services,133 alcohol and drug abuse services,134 and sexual assault 
treatment.135  They may consent to these treatments without parental 
consent.  Two rationales underlie this exception:  (1) the recognition 
of maturity among minors who seek certain treatments and (2) the 
                                                                                                                                
 127. Id.; see also Wisconsin v. Yoder, 406 U.S. 205, 234 (1972) (recognizing that the 
state cannot abrogate a parent’s right to raise their children, in particular the state 
cannot compel parents to send their children under sixteen to formal high school); 
Pierce v. Soc’y of Sisters, 268 U.S. 510, 534-35 (1925) (holding that a state cannot 
violate due process rights of parents by requiring children attend public school); 
Meyer v. Nebraska, 262 U.S. 390, 399-400 (1923) (holding that the Fourteenth 
Amendment encompasses the right to bring up children). 
 128. See Rosato, The Ultimate Test of Autonomy, supra note 124, at 18 (citing 
Lacey v. Lair, 139 N.E.2d 25, 30 (Ohio 1956)). 
 129. See generally N.Y. PUB. HEALTH LAW § 2504(1)-(4); N.Y. FAM. CT. ACT § 413 
(McKinney 2016); see also Lowe v. Lowe, 888 N.Y.S.2d 163, 164 (N.Y. App. Div. 
2009). 
 130. N.Y. PUB. HEALTH LAW § 2504(3) (pregnant minors may consent to “medical, 
dental, health and hospital services relating to prenatal care”). 
 131. Id. at § 2504(1) (male parents also obtain this right upon becoming a parent). 
 132. Carey v. Population Servs., Int’l, 431 U.S. 678 (1977) (holding that the federal 
right to privacy covers a minor’s decision affecting procreation); FEIERMAN ET AL., 
supra note 111, at 15.  Reproductive healthcare includes family planning (i.e., birth 
control and contraceptives), abortion, pregnancy and prenatal care, and care for 
sexually transmitted infections (“STIs”). See also State Policies in Brief:  Minors’ 
Access to STI Services, GUTTMACHER INST. (Nov. 2011), https://www.guttmacher.
org/state-policy/explore/minors-access-sti-services [https://perma.cc/7F23-4JEX]. 
 133. N.Y. MENTAL HYG. LAW § 33.21 (McKinney 2011). 
 134. Id. at § 22.11. 
 135. FEIERMAN ET AL., supra note 111, at 15. 
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barriers that “parental consent” may present to a minor obtaining 
necessary medical treatment. 
At a certain age, minors are “mature” enough to consent to certain 
medical treatments despite their legal “incapacity.”136  “Mature 
minors” are emotionally and intellectually mature enough to give 
informed consent, and are recognized as a legal category by the 
American Medical Association (“AMA”), American Academy of 
Pediatrics (“AAP”), and by the highest courts of several states.137  
Generally, when courts consider applying this exception to parental 
consent requirements they weigh several factors, such as the minor’s 
age, capabilities, experience, education, training, demeanor, and 
judgment.138  If a minor is seeking medical treatment for reproductive 
health, mental health, or drug and/or alcohol treatment, courts 
typically conclude she has already demonstrated a requisite level of 
maturity.  Moreover, sexual activity and drug use are realities for 
many “legal minors” and, similar to acute health conditions (e.g., 
reproductive health, mental health, and substance abuse), justify the 
statutory exceptions to parental consent requirements. 
New York courts, however, have not formally recognized the 
category of “mature minors” who may obtain medical care without 
parental consent.139  Although, in one case, the Queens County 
Supreme Court applied the mature minor doctrine to determine 
whether a seventeen year old could refuse blood transfusions on 
religious grounds.140  Phillip Malcolm, seven weeks short of his 
eighteenth birthday, required a blood transfusion, but both Mr. 
Malcolm and his parents refused to consent to the transfusion 
because of their beliefs as Jehovah’s Witnesses.141  In response, the 
                                                                                                                                
 136. See Rosato, supra note 124, at 170-71 (collecting literature). 
 137. See, e.g., Opinion 5.055:  Confidential Care for Minors, AM. MED. ASS’N J. OF 
ETHICS (Nov. 2014); Policy Statement:  Informed Consent, Parental Permission, and 
Assent in Pediatric Practice, 95 PEDIATRICS 314, 315-16 (1995); Belcher v. Charleston 
Area Med. Ctr., 422 S.E.2d 827, 837-38 (W. Va. 1992); In re E.G., 549 N.E.2d 322, 328 
(Ill. 1989); Cardwell v. Bechtol, 724 S.W.2d 739, 745 (Tenn. 1987). 
 138. Dalizza D. Marques-Lopez, Note, Not So Gray Anymore:  A Mature Minor’s 
Capacity to Consent to Medical Treatment, U. OF HOUSTON L. CTR. (2006), 
https://www.law.uh.edu/healthlaw/perspectives/2006/(DM)MatureMinor.pdf 
[https://perma.cc/VLS8-XZY2]. 
 139. FEIERMAN ET AL., supra note 111, at 23.  New York also does not have a 
statute that allows a minor to seek emancipation from her parents.  That said, the 
state has recognized minors as emancipated, so long as they live as if emancipated 
(i.e., married, in the military, or economically independent). See FEIERMAN ET AL., 
supra note 111, at 20-21. 
 140. In re Long Island Jewish Med. Ctr., 557 N.Y.S.2d 239, 243 (N.Y. Sup. Ct. 
1990). 
 141. Id. at 240. 
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hospital petitioned the court to authorize its use of necessary medical 
treatment, including blood transfusions.142  The court acknowledged 
that courts in other states, including the Supreme Courts of Illinois 
and Tennessee, have recognized the existence of the mature minor 
doctrine143 and invited the New York legislature or appellate courts 
to clarify its validity in New York State.144  Although the court found 
merit in the “mature minor” doctrine, it refused to apply it to Phillip 
Malcolm because, “his refusal to consent to blood transfusions is not 
based upon a mature understanding of his own religious beliefs or of 
the factual consequences to himself.”145  Despite the court’s 
reluctance to formally recognize the “mature minor” doctrine as 
applicable in New York, one may interpret Phillip Malcolm’s case to 
mean that a mature minor standard does exist in New York State 
because the court held it did not apply to his medical situation.146 
Certain treatment exceptions to parental consent requirements also 
exist because parental consent may create a “significant barrier” to a 
minor accessing medical care.147  Requiring a minor to bring a 
parent’s attention to her need for medical care related to sexually 
transmitted infections (“STIs”), pregnancy, or drug use would create 
volatility within the parent/child relationship.148  Minors would be 
more likely to avoid family conflict at the expense of their health.149  
In fact, one study found that when parental notice was mandated, 
                                                                                                                                
 142. Id. 
 143. Id. at 243 (citing In re E.G., 549 N.E.2d 322 (Ill. 1989); Cardwell v. Bechtol, 
724 S.W.2d 739 (Tenn. 1987)). 
 144. Long Island Jewish Med. Ctr., 557 N.Y.S.2d at 243 (recognizing that minors 
may consent to outpatient mental health services, treatment for substance abuse and 
sexually transmitted infections, and prenatal care or child care for minors with 
children).  The court also recognized New York’s statutory exceptions to the parental 
consent law. 
 145. Id. (“It is recommended that the legislature or the appellate courts take a hard 
look at the ‘mature minor’ doctrine and make it either statutory or decision law in 
New York State.”).  The court also recommended that the determination of whether 
the minor is, in fact, a mature minor should first be established through a preliminary 
hearing; only then should the substance of the matter be adjudicated.  Id. at 243 n.16. 
 146. FEIERMAN ET AL., supra note 111, at 23. 
 147. Id. at 16. 
 148. OFF. OF TECH. ASSESSMENT, U.S. CONG., ADOLESCENT HEALTH-VOL. III:  
CROSS-CUTTING ISSUES IN THE DELIVERY OF HEALTH AND RELATED SERVICES 134 
(June 1991), http://govinfo.library.unt.edu/ota/Ota_2/DATA/1991/9104.PDF 
[https://perma.cc/25L3-KYHR]. 
 149. See FEIERMAN ET AL., supra note 111, at 23. 
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fewer than twenty percent of adolescents sought medical care for 
STIs, pregnancies, or drug use.150 
Medical providers recognize that facilitating access to confidential 
care for STIs prevents harm to both the minor’s health and the public 
health because STIs may be easily transmitted.151  Allowing minors to 
consent to STI treatment enhances the speed of the treatment process 
and helps contain a possible epidemic.152  Currently, preventing the 
harms associated with foregoing mental health (or pre-natal care) and 
substance abuse motivate the statutory exceptions to parental 
consent.  Mental health and substance abuse services are available to 
minors because, when left untreated, both conditions may result in 
harm to both the minor and others.153  Further, parental consent is 
often not practical in treating a minor during periods of extreme 
emotional distress or acute drug use.154  Access to confidential 
medical services increases the likelihood that a minor seeks 
treatment.155  Thus, the state’s prerogatives should align with medical 
providers:  quickly treating health conditions, containing possible 
epidemics, and reducing public health harms, which override parental 
barriers to consent and warrant the existing legal exceptions. 
2. Confidentiality of HIV Testing and Treatment 
Medical providers have a duty to keep patient medical information 
confidential.156  Disclosure without prior consent constitutes 
professional misconduct.157  A minor’s right to confidentiality, just 
like her right to give consent, may be circumscribed.  When a parent 
consents to medical treatment for a minor, information about the 
treatment is generally disclosed to the parent.158  Only in the special 
circumstances where a minor may consent to her own medical 
treatment, a health care provider may withhold information about 
that treatment to parents or other outside parties.159 
                                                                                                                                
 150. Malizio Marks et al., Assessment of Health Needs and Willingness to Utilize 
Health Care Resources of Adolescents in a Suburban Population, 102 J. PEDIATRICS 
456, 459 (1983). 
 151. Vukadinovich, supra note 125, at 671. 
 152. Id. at 686. 
 153. Id. at 682-84. 
 154. Id. at 683-84. 
 155. Id. at 686. 
 156. 8 N.Y.C.R.R. § 29.1; 10 N.Y.C.R.R. § 405.7(c)(13); see also Griffiths v. Metro. 
St. Ry. Co., 171 N.Y. 106, 111 (1st Dep’t 1902). 
 157. N.Y. EDUC. LAW §§ 6509(9), 6511; 8 N.Y.C.R.R. § 29.1(b)(8) (2011). 
 158. See FEIERMAN ET AL., supra note 111, at 25. 
 159. See id. at 26. 
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There are two exceptions to disclosure when parents provide 
consent for a minor’s medical treatment.  First, a medical provider 
must not disclose information that would be detrimental to the 
provider-patient relationship or the parent-minor relationship.160  For 
example, a provider treating a minor for substance abuse must not 
disclose that medical information to a parent who is likely to disrupt 
the minor’s course of treatment.  Second, a medical provider may 
withhold medical information if a minor objects to disclosure and is 
twelve years old or older.161  In this context, disclosure is within the 
provider’s discretion. 
School health services also provide a general exception to 
disclosure.  The federal constitutional right of privacy protected by 
the Fourteenth Amendment prevents the government and its agents 
from disclosing a person’s private information.162  While parents 
generally consent to school-based health services, an adolescent may 
consent to medical care in school, and the school must keep that 
medical information confidential.163  Federal law, however, only 
ensures confidentiality for medical and treatment records maintained 
by school health providers.164  Health records maintained by school 
administrators, such as those related to enrollment in school (e.g., 
state-mandated vaccination records), are accessible to parents.165  
Thus, to ensure confidential medical treatment of minors, school 
health providers should keep confidential health information separate 
from general health information related to education.166 
a. Testing and Confidentiality:  Article 27-f 
In the context of HIV prevention and treatment, concerns about 
confidentiality and mandated disclosure may determine whether a 
patient seeks medical care or advice in the first place.  In 1989, New 
York State enacted Article 27-f of the Public Health Law, addressing 
testing, confidentiality, and disclosure of HIV-related information.167  
                                                                                                                                
 160. N.Y. PUB. HEALTH LAW § 18(2)(c). 
 161. Id. 
 162. See Whalen v. Roe, 429 U.S. 589, 599 n.25 (1977); Sterling v. Minersville, 232 
F.3d 190, 196-97 (3d Cir. 2000) (holding that disclosure of an individual’s sexual 
orientation by a police officer violated the constitutional right to privacy). 
 163. See FEIERMAN ET AL., supra note 111, at 27. 
 164. See id. at 28. 
 165. See 20 U.S.C. § 1232(g) (2013) (denying funds to schools that refuse parents 
access to student records). 
 166. FEIERMAN ET AL., supra note 111, at 28. 
 167. N.Y. PUB. HEALTH LAW §§ 2780-87 (McKinney 2015); see also Wendy A. 
Barnhart, Note, Confidentiality of HIV and AIDS Related Information in New 
York, 1 SYRACUSE J. LEGIS. & POL’Y 115, 115 (1995). 
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Article 27-f mandates “maximum confidentiality”168 for HIV and 
AIDS-related information to encourage voluntary testing and 
treatment, and to protect individuals from diagnosis-based 
discrimination.169 
Article 27-f promotes a policy that seeks to reduce the social harms 
(e.g., stigmatization, discrimination, etc.) associated with a diagnosis 
or treatment.170  Any possible indication of an HIV infection results 
in a range of discrimination against that person predicated on 
“society’s accumulated myths and fears about disability and 
disease.”171  Indeed, people with HIV experience discrimination in 
employment, housing, and even dental and medical care unrelated to 
HIV treatment.172  Discrimination has such a pervasive impact on 
individuals, and on society, that many people forgo testing altogether.  
For example, nearly forty percent of persons at risk of acquiring HIV 
have not been tested.173  Concerns about privacy and discrimination 
play a significant role in a person’s decision to receive an HIV test—
and if that person tests positive, concerns about privacy and 
discrimination influence their decision to pursue treatment. 
HIV testing is an essential precursor to treatment.  New York 
requires a person to give informed consent before an HIV test can be 
administered.174  The law specifically requires medical providers to 
provide information about HIV/AIDS and its treatment, disclose that 
testing is voluntary and that HIV test results are confidential, and 
inform the patient that the law prohibits discrimination based on HIV 
status.175  The law also requires the person who communicates the test 
results to counsel, or refer for counseling, the patient on the 
emotional consequences of test results, discrimination, behavior 
                                                                                                                                
 168. Human Immunodeficiency Virus and AIDS Related Information—
Confidentiality, 1988 N.Y. SESS. LAW SERV. 584 (McKinney) (“The legislature 
recognizes that maximum confidentiality protection for information related to human 
immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome 
(AIDS) is an essential public health measure”). 
 169. Barnhart, supra note 167, at 115. 
 170. See Scott Burris, Law and the Social Risk of Health Care:  Lessons from HIV 
Testing, 61 ALB. L. REV. 831-32 (1998). 
 171. Id. at 831 (citing Sch. Bd. v. Arline, 480 U.S. 273, 284 (1987)). 
 172. Id. at 835; see also Hannah R. Fishman, HIV Confidentiality and Stigma:  A 
Way Forward, 16 U. PA. J. CONST. L. 199, 201 (2013). 
 173. Burris, supra note 170, at 833. 
 174. N.Y. PUB. HEALTH LAW § 2781(1) (2015).  In 2014, the legislature amended 
the law and deleted the “written or, where authorized by this subdivision, oral” 
consent requirement. N.Y. Laws 2014, ch. 60 (Part A), § 2. 
 175. N.Y. PUB. HEALTH LAW § 2781(3)(a)-(g). 
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change, medical treatment, and the need to notify contacts.176  New 
York’s HIV informed consent law attempts to ensure that patients 
understand the “full range of social risks and medical benefits to be 
found in consenting to [the HIV test].”177  Through confidentiality 
protections, it encourages testing and treatment.178 
The statute, however, contains a contradiction in its treatment of 
minors.  Although Article 27-f authorizes minors to consent to HIV 
testing without parental consent,179 it effectively prohibits minors 
from receiving HIV-related treatment without parental consent.180  
The statute defines “capacity to consent” as “an individual’s ability, 
determined without regard to the individual’s age, to understand and 
appreciate the nature and consequences of a proposed health care 
service, treatment, or procedure . . . .”181  Thus, the statute defines 
informed consent without regard to age.  Nevertheless, the statute 
contemplates disclosure to a minor’s parents by expressly authorizing 
medical providers to disclose information to “a person authorized 
pursuant to law to consent to health care for the individual.”182 
Once a medical provider receives HIV-related information about 
an individual, the provider must decide whether disclosure to anyone 
other than the patient is “medically necessary in order to provide 
timely care and treatment.”183  Because Article 27-f does not 
explicitly provide minors with a right to consent to treatment, the 
medical provider may determine that disclosure is “medically 
necessary” if the minor requires HIV-related treatment, but refuses 
to disclose her status to her parent or guardian.  Before disclosing, 
however, the medical provider must give the minor “appropriate 
                                                                                                                                
 176. Id. § 2781(5); see also Elizabeth B. Cooper, Testing for Genetic Traits:  The 
Need for a New Legal Doctrine of Informed Consent, 58 MD. L. REV. 346, 396-97 
(1999). 
 177. Cooper, supra note 176, at 397. 
 178. See generally Cooper, supra note 176, at 400. 
 179. N.Y. PUB. HEALTH LAW § 2781-(a)(1). 
 180. See LEGAL ACTION CTR., HIV/AIDS TESTING, CONFIDENTIALITY & 
DISCRIMINATION:  WHAT YOU NEED TO KNOW ABOUT NEW YORK LAW 9 (2nd ed. 
2012) (stating that Public Health Law Article 27-f does not authorize a minor to 
consent to HIV-related treatment); but see Wing Wah Ho et al., Complexities in HIV 
Consent in Adolescents, 44 CLINICAL PEDIATRICS 473, 476 (2005) (stating that a 
minor’s right to treatment is not clearly defined by the laws in New York, but 
advocates argue that the basis for consent exists in law); see also Laura Gerace & 
Max Colmers, Untitled Report on Article 27-f (2012) (on file with authors). 
 181. N.Y. PUB. HEALTH LAW § 2780(5) (emphasis added). 
 182. Id. at § 2782(1)(a); see also Gerace & Colmers, supra note 180. 
 183. N.Y. PUB. HEALTH LAW § 2782(4)(e)(1). 
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counseling as to the need for such disclosure.”184  If the provider 
determines that disclosure would not be in the minor’s “best interest,” 
the law prohibits disclosure.185 
As written, Article 27-f creates a treatment conundrum.  The law 
mandates that a medical provider arrange for medical treatment for 
an HIV-positive individual—with that individual’s consent or 
another’s consent as authorized by law.186  However, as discussed 
above, disclosure of a minor’s HIV status may create volatility within 
the parent-child relationship.187  Thus, medical providers confront the 
statutory mandates for disclosure, but must also keep a minor’s “best 
interests” in mind.188  Given this tension in the law, many providers 
believe that minors should receive HIV treatment because 
withholding treatment until consent is given by a parent might drive a 
minor from care altogether.189 
b. Treating HIV As an STI So Minors May Consent Without 
Parental Involvement 
In New York, minors may consent to medical treatment related to 
their reproductive health, mental health, or substance abuse.190  
Reproductive healthcare is broadly defined and ranges from 
providing birth control to treating STIs.191  If HIV were classified as 
an STI, minors would be able to seek HIV-related treatment without 
parental consent as part of their reproductive healthcare.  There are 
historical reasons, however, why this approach has not yet been 
adopted. 
In the 1990s, the DOH decided against classifying HIV and AIDS 
as STIs as a means of furthering public health.  By refusing to make 
the classification, the DOH ensured that laws concerning reporting 
and testing would not come into play.192  DOH’s classification took 
                                                                                                                                
 184. Id. at § 2782(4)(e). 
 185. Id. 
 186. Id. at § 2781. 
 187. See discussion supra Section II.B.1. 
 188. See N.Y. PUB. HEALTH LAW § 2782(4)(e). 
 189. See Gerace & Colmers, supra note 180. (discussing interview with healthcare 
provider and adolescent AIDS expert at New York area hospital in September 2011). 
 190. The right of minors to consent to reproductive healthcare without parental 
involvement is derived from the federal right to privacy. See N.Y. MENTAL HYG. 
LAW § 33.21 (right to consent to mental healthcare); N.Y. MENTAL HYG. LAW § 22.11 
(right to consent to substance use or alcohol treatment); Carey v. Population Servs. 
Int’l, 431 U.S. 678 (1977); see also FEIERMAN ET AL., supra note 111, at 15. 
 191. FEIERMAN ET AL., supra note 111, at 15. 
 192. N.Y. St. Soc’y of Surgeons v. Axelrod, 572 N.E.2d 605 (1991).  Today, the risk 
associated with driving the epidemic “further underground” has lessened.  New York 
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place early in the epidemic, before much of the currently available 
treatment options, and reflected the concern among public health 
experts that classifying HIV as an STI had the potential to exacerbate 
the stigma attached to HIV infection and drive the epidemic further 
underground.193 
In response, the Society of Surgeons194 sued the DOH, alleging that 
the agency’s Commissioner acted outside of the realm of his authority 
in failing to classify HIV as a Sexually Transmitted Disease (“STD,” 
i.e., STI).195  New York’s Court of Appeals disagreed.196  The court 
applied the deferential standard of review to which state agencies are 
entitled and held that determining which conditions should be 
classified as STIs fell within the DOH’s discretionary powers and that 
the Commissioner had not abused his discretion.197  But, in the last 
year, Governor Cuomo has proposed amending the DOH’s 
classification to facilitate youth access to HIV-related medication, 
which could enable minors to more readily access PrEP. 
c. Governor Andrew Cuomo’s 2016 Proposal 
In February 2016, New York Governor Andrew Cuomo proposed 
new policies to change parental consent laws for HIV-positive teens 
in need of treatment198 as part of a broader policy to end the AIDS 
epidemic in New York by 2020.199  To combat HIV infections among 
                                                                                                                                
State allows public health officials to discuss partner notification with HIV infected 
patients, prioritizing new diagnoses.  Partners include spouses, sexual contacts, or 
needle-sharing contacts.  Patients are asked to voluntarily notify partners or provide 
partner names for notification purposes.  Partners are informed in person. See N.Y. 
ST. DEP’T OF HEALTH, HIV Reporting and Partner Notification Questions and 
Answers (2013), https://www.health.ny.gov/diseases/aids/providers/regulations/report
ing_and_notification/question_answer.htm#fiftyfive [https://perma.cc/FZS9-CCEJ]. 
 193. Scott Burris, Driving the Epidemic Underground? A New Look at Law and 
the Social Risk of HIV Testing, 12 AIDS & PUB. POL’Y J. 66 (1997). 
 194. The petitioner, New York State Society of Surgeons, consisted of four medical 
societies that consist of New York State physicians. Axelrod, 572 N.E.2d at 606. 
 195. Sexually Transmitted Infections (“STIs”) more accurately describe medical 
conditions that result from sexual activity.  As opposed to Sexually Transmitted 
Diseases (“STDs”), STIs encompass curable infections, which may not cause any 
symptoms.  STDs, on the other hand, alter typical bodily functions. 
 196. See generally Axelrod, 572 N.E.2d at 605. 
 197. Id. at 606. 
 198. GOVERNOR ANDREW M. CUOMO, BUILT TO LEAD:  2016 STATE OF THE STATE 
257-59 (2016), https://www.governor.ny.gov/sites/governor.ny.gov/files/atoms/files/
2016_State_of_the_State_Book.pdf [https://perma.cc/UY7A-MFBS]. 
 199. Jordyn Taylor, NY Gov. Cuomo Is Fighting the Laws Preventing Teens From 
Getting Treatment for HIV, MIC (Jan. 21, 2016), http://mic.com/articles/133128/ny-
gov-cuomo-is-fighting-the-laws-preventing-teens-from-getting-treatment-for-
hiv#.JxNZkcezd [https://perma.cc/DB44-ED5A].  Ending the epidemic would mean 
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teenagers and expand access to treatment, the Governor proposed to 
reclassify HIV as an STI, which would allow minors to consent to 
treatment.200  Governor Cuomo’s proposal also sought to expand 
access to HIV preventative services to all New Yorkers.  If approved 
by New York’s legislature, minors would be able to access PrEP 
without parental consent under the reproductive health exception to 
parental consent laws.201 
Governor Cuomo’s proposal recognizes that expanding the means 
for a minor to access PrEP is central to the “ending the epidemic” 
campaign.  New York has been recognized as a leader in the country 
by advancing public health policies related to the prevention and 
treatment of HIV.  Most recently, New York also has been 
recognized as a national leader in its effort to expand access to 
PrEP.202  Since June 2014, PrEP use among Medicaid enrollees has 
increased 400 percent.203  The Governor’s February 2016 policy 
proposal converges with the policy proposal put forward by this 
Article.  But, as policymakers debate reclassifying HIV as an STI, 
minors should still have access to PrEP without parental consent as a 
reproductive right, guaranteeing privacy in receiving health services 
related to reproductive healthcare. 
III.  BIRTH CONTROL 
Reproductive rights are constitutional rights that protect both 
adults and minors.  As Justice Blackmun wrote in Planned 
                                                                                                                                
reducing the number of new HIV infections to 750 or fewer each year. Id.; see also 
N.Y. ST. DEP’T OF HEALTH, ENDING THE AIDS EPIDEMIC IN NEW YORK STATE 
(2016), http://www.health.ny.gov/diseases/aids/ending_the_epidemic/ [https://perma.
cc/F4LB-45US].  In 2009, New York saw 4609 new HIV infections, but by 2013 that 
number had been reduced to 3512. See BUREAU OF HIV/AIDS EPIDEMIOLOGY, 
AIDS INST., N.Y. ST. DEP’T OF HEALTH, NEW YORK STATE HIV/AIDS 
SURVEILLANCE ANNUAL REPORT:  FOR CASES DIAGNOSED THROUGH DECEMBER 
2013 (2015), http://www.health.ny.gov/diseases/aids/general/statistics/annual/2013/
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cuomo-announces-next-phase-states-plan-end-aids-epidemic [https://perma.cc/P7PP-
WSXV]. 
 200. Governor Cuomo Announces Proposal Increasing Access to HIV Treatment 
for Teens, PRESS OFF. OF GOVERNOR ANDREW CUOMO (Feb. 11, 2016), 
https://www.governor.ny.gov/news/governor-cuomo-announces-proposal-increasing-
access-hiv-treatment-teens [https://perma.cc/LZX8-G673]. 
 201. Id. 
 202. Id. 
 203. Id. 
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Parenthood of Central Missouri v. Danforth, “constitutional rights do 
not mature and come into being magically only when one attains the 
state-defined age of majority.”204  Reproductive rights exist within the 
constitutional right to privacy.  Both adults and minors share the 
constitutional right to privacy.205  The right to privacy ensures 
individual autonomy in rendering life-altering decisions, such as 
whether to receive medical treatment, marry, or procreate (i.e., 
reproductive rights).206  Minors, therefore, have a right to privacy, 
which manifests as patient-physician confidentiality in the medical 
context.207  Although recent Supreme Court decisions have 
provisionally limited the right to privacy,208 minors still have 
reproductive rights that include access to confidential medical or 
contraceptive services without the need for parental consent.209 
This Part discusses the reproductive rights of minors by addressing 
the key case law defining the framework of reproductive rights.  It 
concludes with a discussion of the law’s social impact, including a 
                                                                                                                                
 204. 428 U.S. 52, 75 (1976). 
 205. See Griswold v. Connecticut, 381 U.S. 479, 484-86 (1965) (holding that a 
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constitutional right to marital privacy); see also Planned Parenthood of Cent. Mo., 
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 208. See, e.g., Webster v. Reprod. Health Servs., 492 U.S. 490 (1989) (upholding 
Missouri law that forbade the use of public facilities for all abortions, except as 
necessary to save a woman’s life, and required physicians to perform viability tests on 
fetuses after twenty weeks of gestation); Hodgson v. Minnesota, 497 U.S. 417 (1990) 
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Title X of the federal Public Health Service Act); Planned Parenthood of Se. Pa. v. 
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in path of a woman seeking an abortion of a nonviable fetus”); Ayotte v. Planned 
Parenthood of N. New Eng., 546 U.S. 320 (2006) (vacating and remanding New 
Hampshire law requiring teens to wait forty-eight hours after parental notification for 
an abortion because there was no medical emergency exception); Gonzales v. 
Carhart, 550 U.S. 124 (2007) (upholding Partial-Birth Abortion Ban Act of 2003 and, 
in the face of medical uncertainty, allowing lawmakers to overrule doctor’s medical 
judgment to “promot[e] respect for human life at all stages in the pregnancy”). 
 209. See GUTTMACHER INST., Minors’ Access to Contraceptive Services, supra 
note 207. 
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reduction in teenage pregnancies and changes in popular attitudes 
toward birth control. 
A. Background:  Minors’ Reproductive Rights 
Reproductive healthcare is relevant to both minors and adults.  
Nearly half (forty-six percent) of teenagers, between fifteen and 
nineteen years old, are sexually active (i.e., have had sex at least 
once).210  By age eighteen, most young Americans have had sex.211  
Although parental involvement in a minor’s medical care often is 
prudent, mandated parental involvement in a minor’s reproductive 
healthcare could result in many minors forgoing treatment while 
remaining sexually active.212 
The law recognizes this social reality.  Twenty-one states and the 
District of Columbia allow minors to consent to obtaining 
contraceptive services213 without the involvement of a parent or 
guardian.214  Other states require unique circumstances to exist before 
a minor, on her own, may access contraceptive services.  These 
exceptions include physician-determined necessity, marriage, 
pregnancy or motherhood, or satisfying a “mature minor” 
determination.215  Four states, however, have no explicit policy on a 
minor’s capacity to consent to contraceptive services.216 
                                                                                                                                
 210. American Teens’ Sexual and Reproductive Health, GUTTMACHER INST. (Sept. 
2016), https://www.guttmacher.org/fact-sheet/american-teens-sexual-and-reproducti
ve-health [https://perma.cc/EQS9-2W58]. 
 211. Id. 
 212. See GUTTMACHER INST., Minors’ Access to Contraceptive Services, supra 
note 207. 
 213. The Guttmacher Institute has identified the following as “contraceptive 
services:” oral contraceptives (birth control or morning after pill), injectable, male 
condom, natural family planning, vaginal ring, patch, spermicide, IUD, copper IUD, 
hormonal IUD, diaphragm or cervical cap, and sponge. See Jennifer J. Frost et al., 
supra note 13. 
214. GUTTMACHER INST., Minors’ Access to Contraceptive Services, supra note 
207.  Those states include Alaska, Arizona, Arkansas, California, Colorado, Georgia, 
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Wyoming. Id.  Access to abortion for minors is legally more complex.  Most states 
require parental consent or notification.  Minors, however, have the constitutional 
right to obtain a judicial bypass to parental consent requirements. See Hodgson v. 
Minnesota, 497 U.S. 417 (1990).  The policy goal of not deterring minors from 
seeking health care often motivates policies that eliminate parental consent 
requirements. See B. Jessie Hill, Medical Decision Making by and on Behalf of 
Adolescents:  Reconsidering First Principles, 15 J. HEALTH CARE L. & POL’Y 37, 42-
43 (2012). 
 215. GUTTMACHER INST., Minors’ Access to Contraceptive Services, supra note 
207. 
 216. Id. Those states are North Dakota, Ohio, Rhode Island, and Wisconsin. 
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The U.S. Supreme Court has recognized a constitutional right to 
privacy for certain decisions that applies to both minors and adults.217  
In 1965, Griswold v. Connecticut first recognized a constitutional 
right to privacy in the penumbra of the First, Third, Fourth, Fifth, and 
Ninth Amendments,218 holding that Connecticut could not restrict a 
married couple’s access to birth control219 without intruding on the 
constitutional right to marital privacy.220  Seven years later, 
Eisenstadt v. Baird extended Griswold’s privacy protections by 
invalidating a state statute that prohibited the sale of contraceptives 
to unmarried couples.221  Eisenstadt found that the “goals of deterring 
premarital sex and regulating the distribution of potentially harmful 
articles” were insufficient state interests to justify the legislation.222 
The constitutional right to privacy guarantees independence from 
government interference in making important decisions about 
marriage, procreation, contraception, and child rearing.223  In 
particular, this right to privacy provides the foundation for a minor’s 
right to obtain contraceptive services.224 
When New York tried to regulate a minor’s access to contraceptive 
services, the U.S. Supreme Court struck down the law.  In Carey v. 
Population Services, Int’l, the Supreme Court invalidated a provision 
in New York’s Education Law that prohibited the advertising or sale 
of non-prescription contraceptives to persons under sixteen years 
old.225  The Court held that a law burdening the fundamental decision 
                                                                                                                                
 217. See Planned Parenthood of Cent. Mo. v. Danforth, 428 U.S. 52, 74 (1976) 
(holding that the state may not impose a “blanket provision” requiring parental 
consent for an abortion); Griswold v. Connecticut, 381 U.S. 479, 484-85 (1965) 
(holding that a statute prohibiting the use of contraceptives by married couples 
violated the constitutional right to marital privacy); Roe v. Wade, 410 U.S. 113 (1973) 
(recognizing that the right to privacy covers the decision to bear a child or terminate 
a pregnancy). 
 218. 381 U.S. at 479. 
 219. Id. at 486. 
 220. Id. 
 221. 405 U.S. 438 (1972). 
 222. Id. at 443. 
 223. Carey v. Population Servs. Int’l, 431 U.S. 678, 684-85 (1977) (collecting cases).  
“Child rearing” involves the custody, care, and control of a child, which has also 
appeared in cases that address a parent’s decision on how to educate their child. See, 
e.g., Wisconsin v. Yoder, 406 U.S. 205, 234-35 (1972) (recognizing that a state cannot 
compel parents to send children to formal high school until age sixteen). 
 224. Carey, 431 U.S. at 694 (holding that blanket parental consent requirements on 
contraceptive services were unconstitutional); see also Eisenstadt, 405 U.S. at 453-55 
(holding that the prohibition of contraceptive services to single individuals, as 
opposed to the married couples in Griswold, violates the Fourteenth Amendment). 
 225. 431 U.S. at 678. 
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to “bear or beget a child . . . may be justified only by compelling state 
interests, and must be narrowly drawn to express only those 
interests.”226  However, a state restriction on the privacy rights of 
minors is less rigorous, and only requires a “significant,” not 
compelling, state interest because the state has “greater latitude to 
regulate the conduct of children.”227  In Carey, the state’s goal of 
deterring sexual activity among minors did not satisfy the 
“significant” state interest standard.228  Absent a medical necessity to 
prohibit the distribution of contraceptives to minors, a third party 
veto—or “blanket” parental consent requirement—was 
unconstitutional.229  Since Carey, New York State has not imposed 
any restrictions on a minor’s right to access contraceptive services.230 
Although Carey held that a state may not prohibit a minor from 
accessing contraception absent a compelling state interest, the Court 
did not address a minor’s right to access contraception when parents 
or guardians disapprove.231  At least one court has implied that such a 
right exists.232  In Arneth v. Gross, the Southern District of New York 
held that a minor’s constitutional right to privacy includes the right to 
use birth control.233 
Additionally, through Medicaid and Title X, the federal 
government funds clinics that make family planning services available 
                                                                                                                                
 226. Id. at 686; see also Planned Parenthood of Se. Pa. v. Casey, 505 U.S. 833, at 
859 (1992) (quoting Carey, 431 U.S. at 684-85). 
 227. Carey, 431 U.S. at 693 n.15 (citing Prince v. Massachusetts, 321 U.S. 158 
(1944); Ginsberg v. New York, 390 U.S. 629 (1968)). 
 228. Carey, 431 U.S. at 701-02. In Casey, the Supreme Court invalidated 
Pennsylvania’s Abortion Control Act, which required notification of a woman’s 
spouse before undergoing an abortion. 505 U.S. at 895.  Casey found that the spousal 
notification requirement would likely prevent a significant number of women from 
obtaining an abortion—that is, it constituted a “substantial obstacle.” Id. at 893-94.  
The Abortion Control Act, therefore, placed an undue burden on a woman’s right to 
reproductive healthcare.  Id. at 895. 
 229. Carey, 431 U.S. at 693-94; but see Alfonso v. Fernandez, 606 N.Y.S.2d 259 
(N.Y. App. Div. 1993) (holding that condom availability programs in public schools 
must contain a parental opt-out provision).  The implicit “parental consent” 
requirement in Alfonso, however, cannot abrogate minors’ rights under the 
Constitution. See FEIERMAN ET AL., supra note 111, at 38 n.87. 
 230. FEIERMAN ET AL., supra note 111, at 38. 
 231. B. Jessie Hill, Constituting Children’s Bodily Integrity, 64 DUKE L.J. 1295, 
1307 (2015). 
 232. See, e.g., Arneth v. Gross, 699 F. Supp. 450, 452 (S.D.N.Y. 1988); see also 
Brenda D. Hofman, Note, The Squeal Rule:  Statutory Resolution and Constitutional 
Implications – Burdening the Minor’s Right of Privacy, 1984 DUKE L. J. 1325, 1352 
(1984). 
 233. Arneth, 699 F. Supp. at 452. 
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to anyone regardless of age.234  These programs include 
confidentiality safeguards for minors that enable clinics to provide 
contraceptive or reproductive health services without involving 
parents.235  If a minor seeks contraceptive services through a Title X 
health provider, federal law requires that the provider must not 
disclose the details of the minor’s care to their parents.236 
Minors generally do not have a constitutional right to consent to 
therapeutic or non-therapeutic medical interventions.237  In New 
York State, reproductive healthcare—from birth control to STI 
treatment—is an exception to parental consent laws.238  HIV-
prophylactic medication, such as PrEP, should fall within the existing 
reproductive health exception.239  The state DOH—through executive 
order or otherwise—can use a regulatory definition to place PrEP in 
the current reproductive healthcare category.  Strategic litigation is 
also an option to move PrEP within the category of reproductive 
healthcare.  Similar to birth control preventing pregnancies, 
preventing HIV infections works against detrimental long-term health 
consequences.  As the next section discusses, the success of the birth 
control pill is an important example. 
B. Outcomes of Permitting Teen Access to Birth Control 
The constitutional right to privacy protecting a person’s access to 
contraceptive services has reduced teen pregnancies and provided 
women with more control over their reproductive health.  Between 
1990 and 2008, the United States’ rate of teenage pregnancy dropped 
by forty-two percent.240  For women aged fifteen to nineteen years 
                                                                                                                                
 234. See 42 U.S.C. § 300, 1396; see also Heather Boonstra & Elizabeth Nash, 
Minors and the Right to Consent to Health Care, GUTTMACHER INST. (2000), 
http://www.guttmacher.org/pubs/tgr/03/4/gr030404.html [https://perma.cc/Y4EC-
6W65]. 
 235. See New York v. Heckler, 719 F.2d 1191, 1196 (2d Cir. 1983); Boonstra & 
Nash, supra note 234. 
 236. See Boonstra & Nash, supra note 234. 
 237. Hill, supra note 231, at 1313. 
 238. See generally FEIERMAN ET AL., supra note 111, at 37-43. 
 239. Mental health services, drug treatment, STI treatment, and pre-natal care are 
also exceptions to parental consent laws.  Although analogously relevant to receiving 
HIV treatment, this Article does not engage in an analysis of “treatment.”  The 
possibility for such an argument, however, should not be foreclosed.  Instead, the 
focus of this Article is on the “preventative” function of certain reproductive health 
services.  Birth control’s preventative or prophylactic function resembles PrEP in 
practice and in law. See discussion infra Section IV.A. 
 240. See PLANNED PARENTHOOD, REDUCING TEENAGE PREGNANCY 4 (July 2013), 
https://www.plannedparenthood.org/files/6813/9611/7632/Reducing_Teen_Pregnancy.
pdf [https://perma.cc/BP3K-4KK3]. 
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old, this meant a decrease from 117 pregnancies per 1000 women to 
67.8 per 1000.241  Additionally, between 1990 and 2008, use of the 
birth control pill increased from nineteen to thirty-nine percent 
among fifteen to seventeen year olds, and together with increased 
condom usage, has been found responsible for a seventy-seven 
percent decline in teenage pregnancies in that age group.242  Through 
2002, the increased and better use of contraception among teens can 
account for up to eighty-six percent of the decline in teenage 
pregnancies.243 
Beyond a reduction in the rate of teenage pregnancies, the advent 
of the birth control pill has had far-reaching social consequences.  
Despite initial concerns that the convenience of the pill would 
promote promiscuity,244 the pill’s greatest impact has been social and 
economic.  For example, birth control is one of the most 
transformational developments in the business sector in the twentieth 
century.245  One-third of the wage gains women have made since the 
introduction of the pill in the 1960s have been the result of access to 
this form of contraception.246  Absent access to the pill, one estimate 
suggests the decrease in the gap between men and women’s annual 
incomes “would have been 10 percent smaller in the 1980s and 30 
percent smaller in the 1990s.”247  Early access to the pill (i.e., before 
the age of twenty-one) is also a major factor that enables women to 
pursue higher education.248  In 1970, college enrollment was twenty 
percent higher among women who could access the pill legally by the 
                                                                                                                                
 241. Id. 
 242. See id. 
 243. See id. 
 244. See Contraception:  Freedom from Fear, TIME (Apr. 7, 1967), 
http://content.time.com/time/subscriber/article/0,33009,843551,00.html 
[https://perma.cc/A4SQ-BZZD]. 
 245. Kurt Soller, The Birth Control Pill Advanced Women’s Economic Freedom, 
BLOOMBERG BUSINESSWEEK (Dec. 4, 2014), http://www.businessweek.com/articles/
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B53Q-B9NK]. 
 246. Birth Control Has Expanded Opportunity for Women–In Economic 
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PARENTHOOD (June 2015), https://www.plannedparenthood.org/files/1614/3275/8659/
BC_factsheet_may2015_updated_1.pdf [https://perma.cc/4AW8-4XRM]. 
 247. Id. at 1 (citing Adam Sonfield et al., The Social and Economic Benefits of 
Women’s Ability To Determine Whether and When to Have Children, 
GUTTMACHER INST. (2013); Martha J. Bailey et al., The Opt-In Revolution? 
Contraception and the Gender Gap in Wages, NBER Working Paper, No. 17922 
(2012)). 
 248. See Adam Sonfield et al., The Social and Economic Benefits of Women’s 
Ability to Determine Whether and When to Have Children, GUTTMACHER INST. 
(2013). 
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age of eighteen, compared with women who were barred from 
accessing it by law before the age of twenty-one.249  Young women’s 
legal access to the pill before the age of twenty-one also led to an 
increase in women who graduated from college.250 
The pill permitted young women to control their reproductive lives 
and changed the balance of power between men and women in 
American society, significantly furthering the pursuit of gender 
equality and female autonomy.251  Generally, when individuals are 
able to delay having children and can choose to have fewer of them, 
“they tend to be more financially secure and better able to help their 
children succeed.”252  The social and health-related benefits of 
expanding access to the birth control pill are clear.  Comparably, 
expanding the definition of reproductive healthcare to include access 
to HIV-preventative medication could effectuate similar social and 
health-related outcomes among MSM thirteen to twenty-four year 
olds, especially those living in communities of color. 
IV.  CREATING A PREP EXCEPTION IN NEW YORK STATE LAW 
Access to PrEP should fall within the reproductive health 
exception to a minor’s capacity to consent to medical care.  Currently, 
New York State classifies PrEP as HIV-related treatment.  As such, 
minors cannot readily access it without parental consent.  Yet, PrEP 
prevents HIV infections as effectively, if not more effectively, than 
the pill prevents pregnancies.  Although critics have expressed 
concern about the side effects from long-term PrEP use, the potential 
reduction in new HIV infections outweighs these concerns.  This 
section analyzes PrEP through a reproductive rights framework.  It 
also addresses and dispels the potential concerns with providing 
minors access to PrEP. 
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A. PrEP Functionally Resemble Birth Control 
The primary similarity between the pill and PrEP is that they are 
both preventative tools.  Individuals use both to shield themselves 
from adverse bodily consequences.  New York’s current classification 
of PrEP as HIV treatment, which precludes minors from accessing it, 
is a misnomer.  Even though Truvada is a combination of two existing 
medications used to treat HIV, its separately approved use as PrEP 
also makes the drug a prevention tool as opposed to a treatment 
option.  This difference in function is an important one, 
acknowledged by the New York State DOH.253 
New York case law currently conflates treatment and prevention, 
but does so in the context of classifying vaccinations.254  In practice, 
the DOH distinguishes between treatment and prevention in the 
context of minors’ access to STI treatment.255  The DOH recognizes 
that preventative measures and treatment after an STI infection 
occupy different positions on the continuum of care;256 as such, there 
is no reason to exclude PrEP from this classification as prevention.  In 
classifying PrEP as HIV treatment, the DOH ignores its actual 
function.  It is also logically inconsistent with how New York treats 
the prevention of STIs—as procedures distinct from treatment of 
STIs.257 
PrEP has numerous differences from HAART therapy (i.e., 
existing HIV treatment regimens).  Apart from the clear functional 
differences,258 Truvada as PrEP is one pill, taken alone; it has minimal 
potential side effects, and requires less frequent monitoring by 
medical professionals.259  Conversely, HAART is a combination of 
numerous ARVs.  HAART treatment requires routine blood testing 
                                                                                                                                
 253. Legislative Memo:  Regarding Expanding Access to STI Treatment and 
Prevention for Minors, N.Y. CIV. LIBERTIES UNION (Apr. 13, 2015), 
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to check viral load, CD4 counts, CD4/CD8 ratios, and a variety of 
other factors.  HAART treatment also requires more stringent 
monitoring for general well-being, side effects, and other 
complications.  It involves more medications, more potential side 
effects and drug interactions, and larger number of blood tests per 
doctor’s visit than are needed for PrEP.260  Adherence to PrEP is 
simpler than adherence to HAART therapy.261  Precluding minors 
from accessing PrEP by maintaining its classification as HIV 
treatment ignores the fact that taking a once-daily pill prevents HIV 
infection. 
In addition to the similarity as a mode of prevention, PrEP 
resembles the birth control pill in other ways that weigh in favor of 
similar legal treatment.  PrEP and the pill are administered similarly; 
each consists of a daily pill with a similar likelihood of preventing 
respective adverse consequences (i.e., for PrEP it is an HIV infection, 
whereas for birth control, it is unwanted pregnancy).262  PrEP and the 
pill are both harm reduction strategies:  the reality that minors will 
engage in sexual activity, regardless of the risks, demands that the 
state intervene to mitigate the public health risks involved.  Finally, 
both PrEP and the birth control pill rely on compliance with the daily 
regimen for the full effect of the prevention therapy to work.263 
Because PrEP is a prevention tactic, it should be distinguished 
from the HIV treatment known as HAART therapy.  Further, there 
are clear and striking similarities between PrEP and the birth control 
pill.  Each is the functional equivalent of the other and the law should 
treat the two prophylaxes similarly. 
B. Minors Have a Right to Privacy That Covers Access to PrEP 
Under New York law, minors may consent to medical care related 
to their reproductive health without parental notification or 
consent.264  Reproductive healthcare is an exception to parental 
consent laws for two reasons:  (1) a large portion of teenagers are 
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sexually active265 and (2) parental notification or consent 
requirements would deter minors from seeking reproductive 
healthcare.266 
Reproductive healthcare is a broad category.  It includes services 
related to birth control, prenatal care, treatment of STIs, and 
abortions.267  This Article focuses on access to birth control as the key 
reproductive health service.  Because birth control falls within the 
category of reproductive healthcare, minors have a right to access it 
without parental interference. 
As discussed in Section III.A, the constitutional right to privacy 
covers medical treatment related to one’s reproductive health.268  
Through the right to privacy, minors may access birth control without 
parental consent, and generally, medical providers may not disclose 
such information to parents.269  The constitutional right to privacy 
should equally protect a minor’s right to access PrEP. 
Confidentiality already protects medical information related to an 
adult’s decision whether to receive an HIV-test or treatment.270  
Article 27-f exemplifies the importance New York State places on the 
confidentiality of HIV-related medical information.271  These 
confidentiality provisions exist because medical information is always 
sensitive, especially HIV-related information, due to social stigma 
and discrimination.272 
Additionally, in Carey, the Supreme Court recognized that a state 
may not restrict a minor’s privacy rights unless such regulation would 
serve a “significant state interest.”273  The right to privacy covers 
access to contraceptives, which implicate the fundamental right, 
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 271. See discussion supra Section II.B.2.a. 
 272. See Burris, supra note 170, at 831-32. 
 273. Carey, 431 U.S. at 693. 
2017] THE OTHER PILL 763 
shared by minors and adults, to autonomously make decisions that 
impact their reproductive life.274  No “significant state interest” exists 
to restrict a minor’s access to PrEP.275 
Carey had previously declared that deterring sexual activity among 
minors is an insufficient significant interest to preclude their access to 
contraceptives.276  The same should be true for PrEP.  No compelling 
or significant medical reason exists for restricting a minor’s access to 
PrEP.  The FDA has approved PrEP for public consumption studies 
on PrEP-related side effects are inconclusive or show minimal harms, 
and PrEP may be the most efficacious method available to prevent 
HIV-infection.277 
If New York continues to impose barriers limiting a minor’s access 
to PrEP, the current rates of HIV-infections among thirteen to 
twenty-four year olds will likely continue.  If minors had a 
reproductive right to access PrEP without parental consent, HIV-
infection rates may fall precipitously, similar to the drop in teenage 
pregnancies once states expanded minors’ access to birth control.278 
C. Why the Arguments Against Expanding Access to PrEP Are 
Wrong 
This Article argues for an expansion of reproductive rights in order 
to reduce the number of HIV-infections among minors in New York 
State.  Critics, however, may raise concerns that relate to existing 
parental rights, adverse health outcomes, and medication compliance.  
This Section addresses each concern in turn. 
First, critics may invoke the legal rights currently afforded to 
parents.  In general, parents have the right to the care, custody, and 
control of their children.  Several Supreme Court decisions have 
recognized that the Fourteenth Amendment encompasses a parent’s 
right to raise their children as the parent chooses.279  In most cases, a 
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parent must consent before a minor receives medical care, which is 
central to the care of a minor.280  Although care and custody 
rationales also inform “parental consent” requirements, the Supreme 
Court has tended to apply such parental rights in the educational 
context.281 
Minors’ access to PrEP, however, is different than the traditional 
circumstances which would require parental consent.  PrEP is a 
medication designed for persons at risk of an HIV infection.  Sexually 
active teenagers are especially at risk.282  Further, many states 
recognize a distinct category of “mature minors” who have the 
cognitive ability to make decisions that affect their reproductive 
health.283  Even without a legislative “mature minor” category, New 
York State acknowledges the concept in reproductive decision-
making.284  If a minor recognizes that risk, and takes appropriate 
precautionary action in consultation with a medical provider, then a 
minor demonstrates a level of maturity comparable to a person 
eighteen years or older.285  By expanding access to PrEP, the law 
would affirm the principles of autonomy that underlie informed 
consent and encourage minors to pursue medical care—the same 
goals underlying the state’s decision to permit minors to obtain 
reproductive healthcare without parental consent. 
Second, critics may assert that, as is often the case with new drugs 
on the market, there are unanswered questions surrounding PrEP.  
The long-term effects of taking Truvada as PrEP are currently 
unknown.  Ordinarily, Truvada has the potential to cause some 
serious side effects, including lactic acidosis (i.e., build-up of digestive 
acid), serious liver problems, or a greater likelihood of developing 
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either of those.286  Tenofivir, one of the two drugs in Truvada, may 
also lead to decreased bone density over time.287  The lack of answers, 
or the potential negative health outcomes, may fuel PrEP’s critics, 
especially when considering whether to permit a minor to access the 
drug.  Similar concerns were raised, and appropriately dispelled, for 
the birth control pill.288  Although more potent when introduced, the 
birth control pill became safer over time.  Furthermore, the health 
and social benefits in expanding access to the birth control pill for 
teens outweighed the potential concern related to its side effects.289  
PrEP is similar.  PrEP’s potential to reduce the risk of HIV infection 
significantly outweighs the costs of potential negative health 
outcomes.  And, as the medical community continues to research 
PrEP, it will most likely become safer over time. 
As an HIV prevention strategy, PrEP is unparalleled, surpassed in 
efficacy only by sexual abstinence, which has proven an unreliable 
public health strategy among teens.290  Concerns about health 
consequences associated with long-term use should not impede 
healthy individuals from preserving their health; this is especially true 
for minors, who will remain sexually active—with or without PrEP as 
a part of their daily regimen. 
Third, another concern some may raise about minors obtaining 
PrEP is that in order to be fully effective, it requires daily adherence, 
which may be challenging.  Similar arguments have emerged in the 
context of taking the birth control pill on a daily basis.  Education and 
counseling services have bridged the gap in the birth control context, 
and they can be similarly effective in the context of PrEP.  Over time, 
teens have come to understand that if they want to avoid pregnancies, 
they need to maintain their daily regimen.291  A considerable 
reduction in the number of teenage pregnancies supports this 
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understanding.  Currently, PrEP is relatively unknown to the groups 
that may most require it.  An increase in education and awareness will 
likely be as effective as promoting daily adherence to PrEP as it was 
for the birth control pill.292 
Additionally, the CDC estimates that the cost of lifetime treatment 
of an HIV infection is $379,668.293  PrEP has been shown to be very 
cost-effective in studies conducted outside of the United States, 
cementing itself as an important public health strategy for the 
prevention of HIV transmission among individuals of all ages.294 
The legal and medical communities should embrace the expansion 
of access to PrEP to minors.  Doing so will help reduce HIV 
infections and save lives.  But, more significantly, it makes sense from 
a legal and policy perspective. 
CONCLUSION 
PrEP’s introduction to the market has been an important milestone 
in the fight against HIV/AIDS.  PrEP has reinvigorated the hope that 
the end of the epidemic is in sight.  Governor Andrew Cuomo’s 
administration has endorsed and outlined a plan to expand access to 
PrEP to minors by reclassifying HIV as an STI.  Another viable 
approach is to include PrEP within the reproductive health exception 
to parental consent through a DOH regulation or affirmative 
litigation.  PrEP and the birth control pill are functionally similar:  
both are a once daily pill that ensure a person’s reproductive health.  
The law must recognize this similarity and codify access to PrEP as a 
matter of reproductive health, ensuring that minors have the ability to 
access PrEP to protect themselves against HIV.  By applying a 
reproductive rights analysis in this context, New York will be one step 
closer towards ending the AIDS epidemic and preserving individual 
autonomy in medical care. 
                                                                                                                                
 292. See id. at 5. 
 293. See HIV Cost-effectiveness, CTRS. FOR DISEASE CONTROL & PREVENTION 
(2015), http://www.cdc.gov/hiv/programresources/guidance/costeffectiveness/index.
html [https://perma.cc/N9M9-4XB9] (calculating the cost of HIV treatment in 2010 
U.S. dollars). 
 294. See, e.g., Estelle Ouellet et al., Cost effectiveness of ‘on demand HIV pre-
exposure prophylaxis for non-injection drug-using men who have sex with men in 
Canada, 26 CAN. J. OF INFECTIOUS DISEASES & MED. MICROBIOLOGY 1, 23 (2015) 
(finding that the average annual total cost of one HIV infection ranged from $27,410 
to $35,358, while the annual cost of PrEP was $12,001 per participant, and the amount 
per life saved was roughly $621,390 per infection prevention.). 
